Phreesia (PHR) S-1 10 Dec 19 IPO registration Financial data

Cover

Cover	9 Months Ended
	Oct. 31, 2019
Cover page.
Document Type	S-1
Amendment Flag	false
Document Period End Date	Oct. 31, 2019
Entity Registrant Name	PHREESIA, INC.
Entity Central Index Key	0001412408
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Balance sheets

Balance sheets - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Current:
Cash and cash equivalents	$ 91,389	$ 1,543	$ 10,503
Settlement assets	10,384	10,217	8,677
Accounts receivable, net of allowance for doubtful accounts	20,008	16,109	12,309
Deferred contract acquisition costs	1,631	1,673	1,640
Prepaid expenses	5,287	3,340	2,826
Total current assets	128,699	32,882	35,955
Property and equipment, net of accumulated depreciation and amortization	14,364	14,211	13,170
Capitalized Internal-use software, net of accumulated amortization	8,501	7,816	6,715
Deferred contract acquisition costs	1,512	1,521	694
Intangibles assets, net of accumulated amortization	1,258	1,437	0
Goodwill	251	250	0
Other assets	1,324	1,145	602
Total assets	155,909	59,262	57,136
Current:
Settlement obligations	10,384	10,217	8,677
Current portion of long term debt	0	97	1,167
Current portion of capital leases	2,413	1,869	1,662
Accounts payable	5,949	4,160	2,203
Accrued expenses	8,018	5,098	6,388
Dividend payable	0	0
Deferred revenue	5,326	6,488	4,886
Total current liabilities	32,090	27,929	24,983
Long term debt, net of current portion	19,355	27,918	19,453
Capital leases, net of current portion	1,971	2,401	652
Warrant liability	0	5,498	3,440
Total liabilities	53,416	63,746	48,528
Commitments and contingencies
Redeemable preferred stock:
Redeemable preferred stock value	0	206,490	176,291
Stockholders' Equity (Deficit):
Common stock value	359	20	16
Additional paid-in capital	382,951
Accumulated deficit	(280,817)	(210,994)	(167,699)
Total stockholders' equity (deficit)	102,493	(210,974)	(167,683)
Total Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)	155,909	59,262	57,136
Senior A Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	79,311	57,022
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	51,872	43,962
Junior Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	32,746	32,746
Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	$ 0	$ 42,561	$ 42,561

Balance sheets (Parenthetical)

Balance sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Allowance for doubtful accounts	$ 729	$ 517	$ 542
Accumulated depreciation and amortization, Property and equipment	34,304	27,862	20,333
Accumulated amortization, Capitalized internal-use software	18,266	14,621	10,612
Accumulated amortization, Intangible assets	$ 212	$ 33	$ 0
Temporary equity, shares outstanding		98,178,078	98,178,078
Common stock, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	80,000,000	80,000,000
Common stock, shares issued	35,759,355	1,994,721	1,638,331
Common stock, shares outstanding	35,759,355	1,994,721	1,638,331
Senior A Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Temporary equity, shares authorized	0	14,500,000	14,500,000
Temporary equity, shares issued	0	13,674,365	13,674,365
Temporary equity, shares outstanding	0	13,674,365	13,674,365
Liquidation value		$ 41,512
Series B Redeemable Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Temporary equity, shares authorized	0	10,820,169	10,820,169
Temporary equity, shares issued	0	9,197,142	9,197,142
Temporary equity, shares outstanding	0	9,197,142	9,197,142
Liquidation value		$ 37,357
Junior Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Temporary equity, shares authorized	0	34,000,000	34,000,000
Temporary equity, shares issued	0	32,746,041	32,746,041
Temporary equity, shares outstanding	0	32,746,041	32,746,041
Liquidation value		$ 32,746
Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Temporary equity, shares authorized	0	44,000,000	44,000,000
Temporary equity, shares issued	0	42,560,530	42,560,530
Temporary equity, shares outstanding	0	42,560,530	42,560,530
Liquidation value		$ 42,561

Statements of operations

Statements of operations - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Revenue:
Revenues	$ 91,968	$ 73,406	$ 99,889	$ 79,834
Expenses:
Cost of revenue (excluding depreciation and amortization)	12,594	10,632	15,105	12,562
Payment processing expense	20,952	16,309	21,892	17,209
Sales and marketing	24,170	19,971	26,367	24,761
Research and development	13,762	10,144	14,349	11,377
General and administrative	20,849	14,118	20,076	18,838
Depreciation	6,444	5,515	7,552	6,832
Amortization	3,823	2,912	4,042	2,808
Total expenses	102,594	79,601	109,382	94,387
Operating loss	(10,626)	(6,195)	(9,494)	(14,553)
Other income (expense)	(740)	167	(7)	602
Change in fair value of warrant liability	(3,307)	(1,496)	(2,058)	(598)
Interest income (expense)	(1,769)	(2,459)	(3,504)	(3,642)
Total other income (expense)	(5,816)	(3,788)	(5,568)	(3,639)
Loss before provision for income taxes	(16,442)	(9,983)
Provision for income taxes	(183)	0
Net loss	(16,625)	(9,983)	(15,062)	(18,192)
Preferred stock dividend paid	(14,955)	0
Accretion of redeemable preferred stock	(56,175)	(20,962)	(30,199)	(19,981)
Net loss attributable to common stockholders	$ (87,755)	$ (30,945)	$ (45,261)	$ (38,173)
Net loss per share attributable to common shareholders, basic and diluted	$ (5.85)	$ (26.30)	$ (24.53)	$ (24.81)
Weighted-average common share outstanding, basic and diluted	15,007,247	1,176,833	1,844,929	1,538,600
Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)			$ (0.53)
Pro forma weighted-average common shares outstanding, basic and diluted (unaudited)			28,322,962
Subscription And Related Services [Member]
Revenue:
Revenues	$ 41,292	$ 31,391	$ 43,928	$ 32,430
Payment Processing Fees [Member]
Revenue:
Revenues	34,781	27,478	36,881	28,671
Life Sciences [Member]
Revenue:
Revenues	$ 15,895	$ 14,537	$ 19,080	$ 18,733

Statements of redeemable prefer

Statements of redeemable preferred stock and stockholders' equity (deficit) - USD ($) $ in Thousands	Total	Redeemable Series A Preferred Stock [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Junior Convertible Preferred Stock [Member]	Redeemable Preferred Stock [Member]	Total Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning Balance at Jan. 31, 2017	$ (130,462)						$ 15		$ (130,477)
Beginning Balance at Jan. 31, 2017		$ 48,544		$ 32,718	$ 42,561	$ 123,823
Beginning Balance, Shares at Jan. 31, 2017							1,494,731
Beginning Balance, Shares at Jan. 31, 2017		13,674,365		32,718,098	42,560,530
Net loss	(18,192)								(18,192)
Issuance of redeemable convertible preferred stock			$ 32,459			32,459
Stock-based compensation expense	805							$ 805
Issuance of redeemable convertible preferred stock, Shares			9,197,142
Exercise of stock options	147						$ 1	146
Net exercise of warrants				$ 28		28
Exercise of stock options Shares							143,600
Net exercise of warrants, Shares				27,943
Accretion of redeemable preferred stock		$ 8,478	$ 11,503			19,981
Accretion of redeemable preferred stock	(19,981)							(951)	(19,030)
Ending Balance at Jan. 31, 2018	$ 176,291	$ 57,022	$ 43,962	$ 32,746	$ 42,561	176,291
Ending Balance, Shares at Jan. 31, 2018	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance at Jan. 31, 2018	$ (167,683)						$ 16		(167,699)
Ending Balance, Shares at Jan. 31, 2018							1,638,331
Net loss	(3,224)								(3,224)
Stock-based compensation expense	252							252
Exercise of stock options	146						$ 1	145
Exercise of stock options Shares							131,560
Accretion of redeemable preferred stock		$ 1,406	$ 1,084			2,490
Accretion of redeemable preferred stock	(2,490)							(397)	(2,093)
Ending Balance at Apr. 30, 2018		$ 58,428	$ 45,046	$ 32,746	$ 42,561	178,781
Ending Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance at Apr. 30, 2018	(172,999)						$ 17		(173,016)
Ending Balance, Shares at Apr. 30, 2018							1,769,891
Beginning Balance at Jan. 31, 2018	(167,683)						$ 16		(167,699)
Beginning Balance at Jan. 31, 2018	$ 176,291	$ 57,022	$ 43,962	$ 32,746	$ 42,561	176,291
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Beginning Balance, Shares at Jan. 31, 2018	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Net loss	$ (9,983)
Cashless exercise of common stock warrants	0
Ending Balance at Oct. 31, 2018		$ 72,350	$ 49,596	$ 32,746	$ 42,561	197,253
Ending Balance, Shares at Oct. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance at Oct. 31, 2018	(197,353)						$ 19		(197,372)
Ending Balance, Shares at Oct. 31, 2018							1,944,445
Beginning Balance at Jan. 31, 2018	(167,683)						$ 16		(167,699)
Beginning Balance at Jan. 31, 2018	$ 176,291	$ 57,022	$ 43,962	$ 32,746	$ 42,561	176,291
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Beginning Balance, Shares at Jan. 31, 2018	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Net loss	$ (15,062)								(15,062)
Stock-based compensation expense	1,447							1,447
Exercise of stock options	361						$ 3	358
Exercise of stock options Shares							316,063
Issuance of common stock in connection with acquisition	163						$ 1	162
Accretion of redeemable preferred stock		$ 22,289	$ 7,910			30,199
Issuance of common stock in connection with acquisition, Shares							40,327
Accretion of redeemable preferred stock	(30,199)							(1,967)	(28,232)
Ending Balance at Jan. 31, 2019	$ 206,490	$ 79,311	$ 51,872	$ 32,746	$ 42,561	206,490
Ending Balance, Shares at Jan. 31, 2019	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance at Jan. 31, 2019	$ (210,974)						$ 20		(210,994)
Ending Balance, Shares at Jan. 31, 2019							1,994,721
Beginning Balance at Apr. 30, 2018	(172,999)						$ 17		(173,016)
Beginning Balance at Apr. 30, 2018		$ 58,428	$ 45,046	$ 32,746	$ 42,561	178,781
Beginning Balance, Shares at Apr. 30, 2018							1,769,891
Beginning Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Net loss	(2,587)								(2,587)
Stock-based compensation expense	252							252
Exercise of stock options	12							12
Exercise of stock options Shares							16,057
Accretion of redeemable preferred stock		$ 6,961	$ 2,275			9,236
Accretion of redeemable preferred stock	(9,236)							(264)	(8,972)
Ending Balance at Jul. 31, 2018		$ 65,389	$ 47,321	$ 32,746	$ 42,561	188,017
Ending Balance, Shares at Jul. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance at Jul. 31, 2018	(184,558)						$ 17		(184,575)
Ending Balance, Shares at Jul. 31, 2018							1,785,948
Net loss	(4,172)								(4,172)
Stock-based compensation expense	447							447
Exercise of stock options	166						$ 2	164
Exercise of stock options Shares							158,497
Accretion of redeemable preferred stock		$ 6,961	$ 2,275			9,236
Accretion of redeemable preferred stock	(9,236)							(611)	(8,625)
Ending Balance at Oct. 31, 2018		$ 72,350	$ 49,596	$ 32,746	$ 42,561	197,253
Ending Balance, Shares at Oct. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance at Oct. 31, 2018	(197,353)						$ 19		(197,372)
Ending Balance, Shares at Oct. 31, 2018							1,944,445
Beginning Balance at Jan. 31, 2019	(210,974)						$ 20		(210,994)
Beginning Balance at Jan. 31, 2019	$ 206,490	$ 79,311	$ 51,872	$ 32,746	$ 42,561	206,490
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Beginning Balance, Shares at Jan. 31, 2019	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Net loss	$ (6,695)								(6,695)
Stock-based compensation expense	599							599
Exercise of stock options	37							37
Exercise of stock options Shares							29,798
Issuance of common stock warrants	833							833
Accretion of redeemable preferred stock		$ 5,196	$ 2,667			7,863
Accretion of redeemable preferred stock	(7,863)							(1,469)	(6,394)
Ending Balance at Apr. 30, 2019		$ 84,507	$ 54,539	$ 32,746	$ 42,561	214,353
Ending Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance at Apr. 30, 2019	(224,063)						$ 20		(224,082)
Ending Balance, Shares at Apr. 30, 2019							2,024,519
Beginning Balance at Jan. 31, 2019	(210,974)						$ 20		(210,994)
Beginning Balance at Jan. 31, 2019	$ 206,490	$ 79,311	$ 51,872	$ 32,746	$ 42,561	206,490
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Beginning Balance, Shares at Jan. 31, 2019	98,178,078	13,674,365	9,197,142	32,746,041	42,560,530
Net loss	$ (16,625)
Cashless exercise of common stock warrants	2,521
Ending Balance at Oct. 31, 2019	0	$ 0	$ 0	$ 0	$ 0	0
Ending Balance, Shares at Oct. 31, 2019		0	0	0	0
Ending Balance at Oct. 31, 2019	102,493						$ 359	382,951	(280,817)
Ending Balance, Shares at Oct. 31, 2019							35,872,057
Beginning Balance at Apr. 30, 2019	(224,063)						$ 20		(224,082)
Beginning Balance at Apr. 30, 2019		$ 84,507	$ 54,539	$ 32,746	$ 42,561	214,353
Beginning Balance, Shares at Apr. 30, 2019							2,024,519
Beginning Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Net loss	(7,493)								(7,493)
Stock-based compensation expense	1,467							1,467
Exercise of stock options	41							41
Exercise of stock options Shares							22,038
Accretion of redeemable preferred stock		$ 27,510	$ 20,802			48,312
Accretion of redeemable preferred stock	(48,312)							(1,508)	(46,804)
Payment of preferred stock dividends	(14,955)							(14,955)
Issuance of common stock in initial public offering, net of issuance costs	124,697						$ 78	124,619
Issuance of common stock in initial public offering, net of issuance costs, shares							7,812,500
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	262,665	$ (112,018)	$ (75,341)	$ (32,746)	$ (42,561)	(262,665)	$ 253	262,412
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock, shares		(13,674,365)	(9,197,142)	(32,746,041)	(42,560,530)		25,311,535
Conversion and exercise of preferred stock warrants into common stock	8,805						$ 6	8,799
Conversion and exercise of preferred stock warrants into common stock Shares							588,763
Ending Balance, Shares at Jul. 31, 2019		0	0	0	0
Ending Balance at Jul. 31, 2019	102,852						$ 357	380,875	(278,380)
Ending Balance, Shares at Jul. 31, 2019							35,759,355
Net loss	(2,437)								(2,437)
Stock-based compensation expense	1,766							1,766
Exercise of stock options	366						$ 1	365
Exercise of stock options Shares							59,679
Cashless exercise of common stock warrants	2						$ 1	1
Cashless exercise of common stock warrants Shares							53,023
Deferred offering costs	(56)							(56)
Ending Balance at Oct. 31, 2019	0	$ 0	$ 0	$ 0	$ 0	$ 0
Ending Balance, Shares at Oct. 31, 2019		0	0	0	0
Ending Balance at Oct. 31, 2019	$ 102,493						$ 359	$ 382,951	$ (280,817)
Ending Balance, Shares at Oct. 31, 2019							35,872,057

Statements of redeemable pref_2

Statements of redeemable preferred stock and stockholders' equity (deficit) (Parenthetical) $ in Thousands	Jan. 31, 2018USD ($)
Total Redeemable Preferred Stock [Member]
Deferred offering costs	$ 1,540,783

Statements of cash flows

Statements of cash flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (16,625)	$ (9,983)	$ (15,062)	$ (18,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,267	8,427	11,594	9,640
Stock-based compensation expense	3,832	950	1,447	805
Change in fair value of warrants liability	3,307	1,496	2,058	598
Amortization of debt discount	412	579	798	904
Loss on extinguishment of debt	1,073	0
Cost of Phreesia hardware purchased by customers	512	0	585	0
Deferred contract acquisition costs amortization	1,465	1,179	1,640	1,389
Changes in operating assets and liabilities
Accounts receivable	(3,899)	(346)	(3,800)	(3,382)
Prepaid expenses and other assets	(2,943)	130	(540)	(319)
Deferred contract acquisition costs	(1,414)	(1,468)	(861)	(383)
Accounts payable	1,629	1,208	1,957	(2,058)
Accrued expenses	3,098	(145)	(1,908)	1,968
Deferred revenue	(1,162)	(359)	1,602	(723)
Net cash provided by (used in) operating activities	(448)	1,668	(2,130)	(11,142)
Cash flows used in investing activities:
Acquisition			(1,190)	0
Capitalized internal-use software	(4,329)	(3,744)	(5,109)	(5,375)
Purchase of property and equipment	(4,826)	(3,397)	(4,724)	(6,590)
Net cash used in investing activities	(9,155)	(7,141)	(11,023)	(11,965)
Cash flows from financing activities:
Proceeds from IPO	130,781	0
Proceeds from revolving line of credit	9,876	3,500	14,800	12,400
Payments of revolving line of credit	(17,676)	(3,500)	(7,000)	(20,400)
Proceeds from term loan	20,000	0	0	10,000
Repayment of term loan	(1,042)	(875)	(1,167)	(1,167)
Repayment of loan payable	(20,000)	0
Payment of preferred stock dividends	(14,955)	0
Payment on capital leases	(1,624)	(1,870)	(2,470)	(1,929)
Debt extinguishment costs	(300)	0
Debt issuance costs	(112)	0	(136)	(224)
Proceeds from issuance of preferred stock, net			0	32,459
Proceeds from issuance of common stock upon exercise of stock options	445	324	361	147
Deferred offering costs	(5,944)	0	(195)	0
Net cash (used in) provided by financing activities	99,449	(2,421)	4,193	31,286
Net increase (decrease) in cash and cash equivalents	89,846	(7,894)	(8,960)	8,179
Cash and cash equivalents-beginning of period	1,543	10,503	10,503	2,323
Cash and cash equivalents-end of period	91,389	2,609	1,543	10,503
Supplemental information:
Property and equipment acquisitions through capital leases	1,738	2,053	4,425	781
Deferred debt issuance costs included in accrued expenses	0	0	0	100
Purchase of property and equipment included in accounts payable	546	0
Deferred issuance costs included in accounts payable and accrued expenses			344	0
Issuance of warrants related to debt	833	0
Shares issued in connection with acquisition			162	0
Cashless exercise of common stock warrants	2,521	0
Net exercise of preferred stock warrant			0	28
Cash payments for:
Interest	$ 1,834	$ 1,732	$ 2,799	$ 2,816

Background and liquidity

Background and liquidity	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	1. Background and liquidity (a) Background Phreesia, Inc. (the Company) is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the Phreesia Platform), the Company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a leading payments solution for secure processing of patient payments. The Company’s Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. The Company was formed in May 2005, and has its corporate headquarters in New York, and operations offices in Raleigh, North Carolina and Ottawa, Canada. (b) Initial public offering On July 22, 2019, the Company closed its initial public offering (IPO), in which the Company issued and sold 7,812,500 shares of common stock at a public offering price of $18.00 per share, resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions of $9,844 but before deducting deferred offering costs of $6,084. In addition to the shares of common stock sold by the Company upon the IPO, certain selling stockholders sold an aggregate of 2,868,923 shares of common stock as part of the IPO. Upon closing of the IPO, the Company’s outstanding shares of Senior A redeemable convertible preferred stock (Senior A Preferred), Senior B redeemable convertible preferred stock (Senior B Preferred, and together with the Senior A Preferred, the Senior Preferred), and the Junior convertible preferred stock (the Junior Preferred, and together with the Senior Preferred, the Convertible Preferred) automatically converted into shares of common stock and all of the outstanding shares of the Company’s redeemable preferred stock (Redeemable Preferred) were automatically extinguished and cancelled at the closing of the IPO. In addition, the Company’s warrants to purchase shares of Senior Preferred were converted into warrants to purchase shares of the Company’s common stock upon the closing of the IPO. Additionally, 588,763 shares of common stock were issued upon the cashless exercise of common stock warrants (See Note 10). Also, in connection with the IPO, the Company paid $14,955 in dividends to the Senior Preferred stockholders. (c) Recapitalization The Company effected a 0.4551-for-1 (d) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of preferred stock and debt, and most recently with proceeds from the IPO, to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at October 31, 2019, along with cash generated in the normal course of business, and available borrowing capacity under its February 2019 Credit Facility (See Note 6), are sufficient to fund its operations for at least the next 12 months. The Company will obtain additional financing if needed to successfully implement its long-term strategy. There can be no assurance that additional financing, if needed, can be obtained on terms acceptable to the Company. The ability of the Company to achieve successful operations will depend on, among other things, new business, the retention of customers, and the effectiveness of sales and marketing initiatives. The Company is subject to a number of risks similar to other companies in its stage of business life cycle, including dependence on key individuals, competition in the marketplace, and the need to fund future product and services development.	1. Background and liquidity (a) Background Phreesia, Inc. (the “Company”) is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the “Phreesia Platform”), the Company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and an integrated payments solution for secure processing of patient payments. The Company’s Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. The Company was formed in May 2005, and has its corporate headquarters in New York, and operations offices in Raleigh, North Carolina and Ottawa, Canada. (b) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of preferred stock and debt to fund its operations as well as sales in the normal course of business. Management believes that losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at January 31, 2019 along with cash generated in the normal course of business, and available borrowing capacity under its February 2019 Credit Facility (Note 5), are sufficient to fund its operations through at least April 2020. Additional financing may be required for the Company to successfully implement its long-term strategy. There can be no assurance that additional financing, if needed, can be obtained on terms acceptable to the Company. The ability of the Company to achieve successful operations will depend on, among other things, new business, the retention of customers, and the effectiveness of sales and marketing initiatives. The Company is subject to a number of risks similar to other companies in its stage of business life cycle, including dependence on key individuals, competition from established companies, and the need to fund future product and services development. (c) Recapitalization The Company effected a 0.4551-for-1

Basis of presentation

Basis of presentation	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	2. Basis of presentation (a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada. (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively. (c) Unaudited interim financial statements The accompanying financial statements and the related footnote disclosures are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s interim financial position as of October 31, 2019 and the results of its operations and its cash flows for the periods ended October 31, 2018 and 2019. The results for the interim periods are not necessarily indicative of results to be expected for the full year, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited financial statements and accompanying notes for the year ended January 31, 2019.	2. Basis of presentation (a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and include the accounts of Phreesia, Inc. and its branch operation in Canada. (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	3. Summary of significant accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended January 31, 2019. Since the date of those audited financial statements, there have been no changes to the Company’s significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use (b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the nine months ended October 31. (c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight	3. Summary of significant accounting policies (a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use (b) Revenue recognition The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital marketing revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The Company has adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, The Company accounts for revenue from contracts with customers by applying the requirements of Topic 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type. Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare provider organizations that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (“PhreesiaPads”) and on-site non-cancelable Leases In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Stations), on-site Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees. The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. Life sciences The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to targeted patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by revenue source on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees and digital marketing solutions sold to life sciences companies. In addition, all of the Company’s revenue is derived from customers in the United States. Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either: contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). Contract balances Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from its subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract February 1, 2017 $ 78 $ 5,605 Contract asset additions 96 — Amount transferred to receivables from contract assets (68 ) — Increases due to invoicing prior to satisfaction of performance obligations — 2,890 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (3,609 ) January 31, 2018 $ 107 $ 4,886 Contract asset additions 615 — Amount transferred to receivables from contract assets (86 ) — Increases due to invoicing prior to satisfaction of performance obligations — 5,900 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (4,298 ) January 31, 2019 $ 636 $ 6,488 Cost to obtain a contract The Company capitalizes sales commissions paid to internal sales personnel that are incremental to the acquisition of customer contracts. These costs are recorded as deferred contract acquisition costs on the accompanying balance sheets. The Company determines whether costs should be deferred based on its sales compensation plans and if the commissions are incremental and would not have occurred absent the customer contract. Sales commission for subscription and related services are recorded when earned by our sales team. The majority of our sales commissions are considered to be costs of obtaining our customer contracts and as a result are capitalized and then amortized over a period of benefit that the Company has estimated to be three years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,389 and $1,640 for the fiscal years ended January 31, 2018 and 2019, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: January 31, 2018 2019 Beginning balance $ 1,950 $ 2,334 Additions to deferred contract acquisition costs 1,773 2,500 Amortization of deferred contract acquisition costs (1,389 ) (1,640 ) Ending balance $ 2,334 $ 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,640 1,673 Deferred contract acquisition costs, non current 694 1,521 Total deferred contract acquisition costs $ 2,334 $ 3,194 (c) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Platform such as hosting fees, certain fees paid to various third party partners for the use of their technology, and personnel expenses for implementation and technical support. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation. (d) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks and that are ultimately paid to the card-issuing financial institution, assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. (e) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $17 and $134 for the fiscal years ended 2018 and 2019, respectively. (f) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use (g) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. (h) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Stations (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. (i) Amortization Amortization primarily represents amortization of our capitalized internal-use (j) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. (k) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one or two business days of the transaction date. (l) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. (m) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts based on specific account analysis of at-risk Account receivable also includes unbilled accounts receivable (see Contract Balances). (n) Property and equipment Property and equipment, including PhreesiaPads, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three and seven years, with the useful lives of leasehold improvements being the shorter of the useful life of the asset or the life of the underlying lease. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized. Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations. (o) Capitalized internal-use The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC Topic 350-40, Intangibles—Goodwill and Other—Internal use software Internal-use internal-use For fiscal 2018 and fiscal 2019, the Company capitalized $5,375 and $5,109, respectively, of costs related to the Phreesia Platform. During the years ended January 31, 2018 and 2019, amortization expense of capitalized internal-use (p) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the statement of operations. (q) Goodwill and intangible assets Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, it is necessary to perform the two-step two-step “step-one All other intangible assets associated with purchased intangibles, consisting of customer relationships and acquired technology are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. (r) Long-lived assets Long-lived assets, such as property and equipment and intangible assets, including capitalized internal-use (s) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the ASC 740, Accounting for Uncertainty in Income Taxes de-recognition, The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability. The Company determined that there were no unrecognized tax benefits as of January 31, 2018 and 2019. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision (benefit) from income taxes. (t) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the financial statements. (u) Redeemable preferred stock All of the Company’s redeemable preferred stock is classified outside of stockholders’ deficit because the shares contain certain redemption features that are not solely within the control of the Company. At the time of issuance, the redeemable preferred stock is recorded at its issuance price, less issuance costs. The carrying values of the Senior Preferred are being accreted to their redemption values at each reporting period, which is equal to the greater of (i) the original issuance price plus unpaid accrued dividends or (ii) the fair value of the Senior Preferred. The Junior Preferred and Redeemable Preferred were accreted to their redemption amount, which is $1.00 per share. The Company records changes in the redemption value of redeemable preferred stock immediately as they occur as if the end of the reporting period was the redemption date for the instrument. (v) Stock-based compensation The Company recognizes the grant-date fair value of stock-based awards issued as compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to performance or market conditions. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the estimated fair value of the underlying common stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, the most critical of which is the estimated fair value of the Company’s common stock. The estimated fair value of each grant of stock options awarded during the years ended January 31, 2018 and 2019 was determined using the following methods and assumptions: • Estimated fair value of common stock. Valuation of Privately-Held-Company Equity Securities Issued as Compensation • Expected term. Share-Based Payment • Risk-free interest rate. • Expected volatility. • Dividend yield. The inputs and assumptions used to estimate the fair value of stock-based payment awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different inputs and assumptions, the Company’s stock-based compensation expense could be materially different for future awards. (w) Warrant liability Warrants to purchase shares of the Company’s redeemable preferred stock are classified as warrant liability on the accompanying balance sheet and recorded at fair value. This warrant liability is subject to re-measurement paid-in (x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under generally accepted accounting principles. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. (y) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of Cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more 10% of total revenues for fiscal 2018 and fiscal 2019. (z) Deferred offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process paid-in (aa) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured (bb) New accounting pronouncements JOBS Act accounting election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company has elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently adopted accounting pronouncements In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments zero-coupon In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting re-measure 2018-07 Recent accounting pronouncement not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13”). 2018-13 In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight

Composition of certain financia

Composition of certain financial statement captions	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	4. Composition of certain financial statement captions (a) Accrued expenses Accrued expenses as of January 31, 2019 and October 31, 2019 are as follows: January 31, October 31, 2019 2019 Payment processing fees liability $ 2,267 $ 2,428 Commission and bonus 320 2,653 Accrued payment related to acquisition of Vital Score 350 350 Vacation 417 543 Other 1,744 2,044 Total $ 5,098 $ 8,018 (b) Property and equipment Property and equipment as of January 31, 2019 and October 31, 2019 are as follows: Useful life January 31, October 31, 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 22,747 $ 26,470 Computer equipment 3 14,338 17,093 Computer software 3 2,166 2,223 Hardware development 3 1,024 1,024 Furniture and fixtures 7 647 683 Leasehold improvements 2 1,151 1,175 Total property and equipment $ 42,073 $ 48,668 Less accumulated depreciation and amortization (27,862 ) (34,304 ) Property and equipment—net $ 14,211 $ 14,364 Depreciation expense related to property and equipment amounted to $5,515 and $6,444 for the nine months ended October 31, 2018 and 2019, respectively. Capital lease depreciation, included in depreciation expense, was $1,758 for the nine months ended October 31, 2019. Assets under capital leases included in computer equipment were $10,235 and $11,973 as of January 31, 2019 and October 31, 2019. Accumulated amortization of assets under capital leases was $5,639 and $7,127 as of January 31, 2019 and October 31, 2019, respectively. (c) Capitalized internal use software For the nine months ended October 31, 2018 and 2019, the Company capitalized $3,744 and $4,329 of costs related to the Phreesia Platform. During the nine months ended October 31, 2018 and 2019, amortization expense of capitalized internal-use (d) Intangible assets The following presents the details of intangible assets as of January 31, 2019 and October 31, 2019. Useful life (years) January 31, October 31, 2019 2019 Acquired technology gross carrying value 5 $ 490 $ 490 Customer relationship gross carrying value 7 980 980 Total intangible assets $ 1,470 $ 1,470 Less accumulated amortization (33 ) (212 ) Net carrying value $ 1,437 $ 1,258 The remaining useful life for acquired technology in years is 4.8 and 4.1 as of January 31, 2019 and October 31, 2019, respectively. The remaining useful life for customer relationships in years is 6.8 and 6.1 as of January 31, 2019 and October 31, 2019, respectively. Amortization expense associated with intangible assets amounted to $0 and $178 for the nine months ended October, 2018 and 2019, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of October 31, 2019: 2020 (Remaining three months) $ 60 Years ending January 31, 2021 238 2022 238 2023 238 2024 224 2025—thereafter 260 Total $ 1,258 (e) Deferred offering costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company’s IPO. Prior to the IPO, all deferred offering costs were capitalized in other assets on the accompanying balance sheet. Upon the closing of the IPO on July 22, 2019, $6,084 was recorded in stockholders’ deficit as a reduction of additional paid in capital. An additional $56 in deferred offering costs related to the IPO were recorded in stockholder’ deficit as a reduction of paid in capital during the three months ended October 31, 2019. The Company recorded $540 of deferred offering costs within other assets on the accompanying balance sheet as of January 31, 2019. (f) Accounts receivable Accounts receivable as of January 31, 2019 and October 31, 2019 are as follows: January 31, October 31, 2019 2019 Billed $ 15,990 $ 19,759 Unbilled 636 978 Total accounts receivable, gross $ 16,626 $ 20,737 Less allowance for doubtful accounts (517 ) (729 ) Total accounts receivable $ 16,109 $ 20,008	4. Composition of certain financial statement captions (a) Accrued expenses Accrued expenses at January 31, 2018 and 2019 are as follows: January 31, 2018 2019 Payment processing fees liability $ 1,858 $ 2,267 Commission and bonus 2,365 320 Acquisition — 350 Vacation 402 417 Other 1,763 1,744 Total $ 6,388 $ 5,098 (b) Property and equipment Property and equipment at January 31, 2018 and 2019 are as follows: Useful life January 31, 2018 2019 PhreesiaPads and Arrivals Stations 3 $ 19,936 $ 22,747 Computer equipment 3 9,214 14,338 Computer software 3 2,139 2,166 Hardware development 3 709 1,024 Furniture and fixtures 7 612 647 Leasehold improvements 2 893 1,151 Total property and equipment $ 33,503 $ 42,073 Less accumulated depreciation and amortization (20,333 ) (27,862 ) Property and equipment—net $ 13,170 $ 14,211 Depreciation expense related to property and equipment amounted to $6,832 and $7,552 for the years ended January 31, 2018 and 2019, respectively. Assets under capital leases included in computer equipment were $5,810 and $10,235 at January 31, 2018 and 2019, respectively. Accumulated amortization of assets under capital lease was $3,275 and $5,369 at January 31, 2018 and 2019, respectively. (c) Intangible assets The following presents the details of intangible assets as of January 31, 2019. There were no intangible assets as of January 31, 2018. January 31, 2019 Gross carrying Accumulated Net Life Remaining Acquired technology $ 490 $ (14 ) $ 476 5 4.8 Customer Relationship 980 (19 ) 961 7 6.8 $ 1,470 $ (33 ) $ 1,437 Amortization expense associated with intangible assets for the fiscal year ended January 31, 2019 was $33. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2019: Year Ending January 31, 2020 $ 238 2021 238 2022 238 2023 238 2024 224 Thereafter 261 $ 1,437 (d) Goodwill The changes in the carrying amount of goodwill were as follows. There was not any goodwill balance in fiscal 2018. Balance at February 1, 2018 $ — Vital Score Acquisition 250 Balance at January 31, 2019 $ 250 (e) Accounts receivable Accounts Receivable at January 31, 2018 and 2019 are as follows: January 31, 2018 2019 Billed $ 12,744 $ 15,990 Unbilled 107 636 12,851 16,626 Less: Allowance for doubtful accounts (542 ) (517 ) $ 12,309 $ 16,109

Debt

Debt	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Debt Disclosure [Abstract]
Debt	6. Debt As of January 31, 2019 and October 31, 2019, the Company had the following outstanding loan balances: January 31, 2019 October 31, 2019 Term loan $ 1,042 $ 20,000 Line of credit 7,800 — Loan payable 20,000 — Total debt $ 28,842 $ 20,000 Less current maturities (97 ) — Less deferred financing costs (996 ) (983 ) Plus accrued interest — 121 Plus accrued final payment 169 217 Long term debt, net of current portion $ 27,918 $ 19,355 The Company had a loan facility with a commercial bank that provided for a term loan with an original principal amount of $3,500 and a $10,000 revolving line of credit, which was later increased to $20,000. The term loan was interest only, at a floating per annum rate equal to the Prime Rate as quoted by the Wall Street Journal print edition less three-quarters of one percent (0.75%), for 12 months from the date of borrowing followed by 36 monthly payments of principal and interest. The Prime Rate was 5.50% as of January 31, 2019. In addition to principal and interest payments due under the loan facility, the Company was required to make a final payment fee to the lender due upon the earlier of prepayment or maturity of the term loan, which was equal to 5% of the principal balance, or $175 and was paid in connection with the repayment of the term loan. The Company accrued the estimated final payment fee using the effective interest method, with a charge to interest expense of $21 for the nine months ended October 31, 2018 and $6 for the nine months ended October 31, 2019 respectively, over the term loan amortization period. Interest expense related to the term loan was $73 and $16, including amortization of deferred financing costs of $18 and $5, for the nine months ended October 31, 2018 and 2019, respectively. For the nine months ended October 31, 2018, the effective interest rate on the term loan was 5.1%. Borrowings under the term loan were repaid in full with the proceeds from the New Loan Agreement that was entered into on February 28, 2019. Borrowings under the revolving line of credit bore interest at the prime rate plus 1.00% and were limited to the greater of $20,000 or an amount determined pursuant to a borrowing base. The revolving credit facility had a maturity date of November 2019. Borrowings under this facility were collateralized by substantially all of the assets of the Company and the Company was required to comply with certain financial covenants related to this facility. The Company was in compliance with all covenants related to the revolving line of credit as of January 31, 2019 and until the total balance of $17,676 was fully repaid on July 22, 2019 with proceeds from the IPO. Weighted-average borrowings outstanding under the revolving line of credit were $971 and $979 for the nine months ended October 31, 2018 and 2019, respectively. Interest expense under the revolving line of credit was $115 and $166 including amortization of deferred financing costs of $53 and $13, for the nine months ended October 31, 2018 and 2019, respectively. On November 7, 2016, the Company entered into a 5-year On February 28, 2019 (the Effective Date), the Company entered into an Amended and Restated Loan and Security Agreement (the New Loan Agreement) that provides for a $20,000 term loan and a revolving credit facility with up to $25,000 of availability. The proceeds from the New Loan Agreement were used to repay in full the term loan, which had a balance of $1,042 as of January 31, 2019 and the $20,000 outstanding under the Loans Payable. The Company is also permitted to borrow an additional $10,000 term loan (the Term Loan B Advance) and, subject to the bank’s approval, another $15,000 (the Term Loan C Advance) prior to February 28, 2020. The term loans under the New Loan Agreement bear interest, which is payable monthly, at a floating rate equal to the bank’s prime rate plus 1.50% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the prime plus 0.75%. Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021. In addition to principal and interest payments due under the term loans, the Company is required to make a final payment to the lenders due upon the earlier of prepayment or maturity of the term loan, which is equal to 2.75% of the original principal amount. The Company accrues the estimated final payment fee using the effective interest method resulting in a charge to interest expense of $217 for the nine months ended October 31, 2019. In connection with the New Loan Agreement, the Company issued warrants to the lenders to purchase an aggregate of 150,274 shares of common stock at an exercise price of $8.02 per share. The warrants expire in February 2029. The fair value of the warrants of $833 was recorded as a debt discount and is being amortized to interest expense over the term of the new term loan and revolving credit facility. If the Company prepays the term loans prior to their respective scheduled maturities, it will also be required to make prepayment fees to the lenders equal to 3% if prepaid on or before the second anniversary of the Effective Date, 2% if prepaid after the second and on or before the third anniversary of funding or 1% if prepaid after the third anniversary of funding of the principal amounts borrowed. Interest expense related to the term loan under the New Loan Agreement was $1,046, including amortization of deferred financing fees of $103 for the nine months ended October 31, 2019. For the nine months ended October 31, 2019, the effective interest rate on the term loan was 3.9%. The Company accounted for the settlement of the Loans Payable and the term loan as a debt extinguishment and recorded an expense of $1,073, which is included in other income (expense), and is comprised of the write-off Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate. The Company has $25,000 of availability as of October 31, 2019. Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual fee of $100 per year during the first three years of the facility and then $75 per year in years four and five. Interest expense related to the revolving credit facility under the new loan agreement was $342, including amortization of deferred financing fees of $84, for the nine months ended October 31, 2019. The Company is required to pay a fee of 0.15% per year for any unused availability and a termination fee of 1.50% if the revolving credit agreement is terminated prior to its scheduled maturity. The revolving credit facility is due five years from the Effective Date, which is February 28, 2024. The Company’s obligations under the New Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The New Loan Agreement includes a financial covenant that requires the Company to achieve specified revenue levels, as defined, through January 31, 2020, after which time revenue levels for covenants purposes will be determined by the bank based on the Company’s forecast, subject to certain minimums. The Company is also required to maintain certain liquidity levels, as defined. The Company was in compliance with all covenants related to the New Loan Agreement as of October 31, 2019. The New Loan Agreement contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) significant judgments, orders or decrees for payments by the Company not covered by insurance; (vii) incorrectness of representations and warranties; (viii) incurrence of subordinated debt; (ix) revocation of governmental approvals necessary for the Company to conduct its business; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. As of October 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining three months) $ — Year ending January 31, 2021 — 2022 6,111 2023 6,667 2024 6,667 2025—thereafter 555 Total long-term debt payments $ 20,000	5. Debt As of January 31, 2018 and 2019, the Company had the following outstanding loan balances: January 31, 2018 2019 Term loan $ 2,208 $ 1,042 Line of credit — 7,800 Loan payable 20,000 20,000 $ 22,208 $ 28,842 Less current maturities (1,167 ) (97 ) Less deferred financing costs (1,730 ) (996 ) Plus accrued Final payment 142 169 Long term debt, net of current portion $ 19,453 $ 27,918 The Company had a loan facility with a commercial bank that provided for a term loan with an original principal amount of $3,500 and a $10,000 revolving line of credit, which was later increased to $20,000. The term loan was interest only, at a floating per annum rate equal to the Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%), for 12 months from the date of borrowing followed by 36 monthly payments of principal and interest. The Prime Rate was 4.50% and 5.50% as of January 31, 2018 and 2019, respectively. In addition to principal and interest payments due under the Loan facility, the Company was required to make a final payment fee to the lender due upon the earlier of prepayment or maturity of the term loan, which was equal to 5% of the principal balance, or $175. The Company accrued the estimated final payment fee using the effective interest rate, with a charge to interest expense of $51 and $28 for fiscal 2018 and fiscal 2019, respectively, over the term loan amortization period. Interest expense related to the term loan was $245 and $121, including amortization of deferred financing costs of $98 and $23, for fiscal 2018 and fiscal 2019, respectively. For the years ended January 31, 2018 and 2019, the effective interest rate on the term loan was 8.8% and 7.4%, respectively. Borrowings under the term loan were repaid in full with the proceeds from the New Loan Agreement that was entered into on February 28, 2019. Borrowings under the revolving line of credit bore interest at the prime rate plus 1.00% and were limited to the greater of $20,000 or an amount determined pursuant to a borrowing base. The revolving credit facility had a maturity date of November 2019. Borrowings under this facility were collateralized by substantially all of the assets of the Company and the Company was required to comply with certain financial covenants related to this facility. The Company was in compliance with all covenants as of January 31, 2018 and 2019. Weighted-average borrowings outstanding under the revolving line of credit were $8,658 and $971 during fiscal 2018 and fiscal 2019, respectively. Interest expense under the revolving line of credit was $786 and $364, including amortization of deferred financing costs of $248 in both periods, for the years ended January 31, 2018 and 2019, respectively. Borrowings under this facility were repaid in full with proceeds from the New Loan Agreement that was entered into on February 28, 2019. On November 7, 2016, the Company entered into a 5-year On February 28, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Loan and Security Agreement (the New Loan Agreement) that provides for a $20,000 term loan and a revolving credit facility with up to $25,000 of availability. The proceeds from the New Loan Agreement were used to repay in full the term loan, which had a balance of $1,042 at January 31, 2019, the balance due under the line of credit under the prior facility, which was $7,800 at January 31, 2019, and the $20,000 outstanding under the Loans Payable. The Company is also permitted to borrow an additional $10,000 term loan (the “Term Loan B Advance”) and, subject to the bank’s approval, another $15,000 (the “Term Loan C Advance”) prior to February 28, 2020. The term loans under the New Loan Agreement bear interest, which is payable monthly, at a floating rate equal to the bank’s prime rate plus 1.50% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the prime plus 0.75%. Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021. In addition to principal and interest payments due under the term loans, the Company is required to make a final payment to the lenders due upon the earlier of prepayment or maturity of the term loan, which is equal to 2.75% of the original principal amount. If the Company prepays the term loans prior to their respective scheduled maturities, it will also be required to make prepayment fees to the lenders equal to 3% if prepaid on or before the second anniversary of the Effective Date, 2% if prepaid after the second and on or before the third anniversary of funding or 1% if prepaid after the third anniversary of funding of the principal amounts borrowed. Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25 million in the aggregate. Based on the borrowing base formula under the new facility, the Company would have $16,300 of availability at January 31, 2019. Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75% , or 4.75%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual fee of $100 per year during the first three years of the facility and then $75 per year in years four and five. The Company is required to pay a fee of 0.15% per year for any unused availability and a termination fee of 1.50% if the revolving credit agreement is terminated prior to its scheduled maturity. The Company’s obligations under the New Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The New Loan Agreement includes a financial covenant that requires the Company to achieve specified revenue levels, as defined, through January 31, 2020, after which time revenue levels for covenants purposes will be determined by the bank based on the Company’s forecast, subject to certain minimums. The Company is also required to maintain certain liquidity levels, as defined. The New Loan Agreement contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) significant judgments, orders or decrees for payments by the Company not covered by insurance; (vii) incorrectness of representations and warranties; (viii) incurrence of subordinated debt; (ix) revocation of governmental approvals necessary for the Company to conduct its business; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. In connection with the New Loan Agreement, the Company issued warrants to the lenders to purchase an aggregate of 150,274 shares of common stock at an exercise price of $8.02 per share. The warrants expire in February 2029. The Company classified all of its borrowings as of January 31, 2019 as long-term debt based on the refinancing under the New Loan Agreement, with the exception of the $97 paid under the prior facility in February 2019 prior to the refinancing. As of January 31, 2019, the Company’s long-term debt is payable as follows (based on the terms of the New Loan Agreement): Year Ending January 31, 2020 $ 97 2021 — 2022 6,111 2023 6,667 2024 6,667 Thereafter 9,300 28,842 Less current portion (97 ) $ 28,745

Common stock

Common stock	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Common Stock [Member]
Common stock	7. Common stock The Company closed an IPO on July 22, 2019 and filed an amended and restated certificate of incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. Upon completion of the IPO, the Company issued and sold 7,812,500 shares of common stock at an issuance price of $18.00 per share resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions. In addition, all outstanding shares of Convertible Preferred stock converted into 25,311,515 shares of common stock (See Note 8) and the Company issued 588,763 shares of common stock as a result of the cashless exercise of warrants (See Note 10). An additional 53,023 shares of common stock were issued as a result of the cashless exercise of warrants as of October 31, 2019 (See Note 10).	6. Common stock The Company’s Sixth Amended and Restated Certificate of Incorporation, as amended, authorizes the issuance of up to 80,000,000 shares of common stock, par value of $0.01 per share. Each share of common stock is entitled to one vote per share, pursuant to certain restrictions. January 31, 2018 2019 Shares Amount Shares Amount Common stock 1,638,331 $ 16 1,994,721 $ 20 As of January 31, 2018 and 2019, the Company has reserved the following shares of common stock for future issuance: January 31, 2018 2019 Senior redeemable convertible preferred stock (Senior A) 6,223,202 6,223,202 Senior redeemable convertible preferred stock (Senior B) 4,185,616 4,185,616 Junior convertible preferred stock 14,902,717 14,902,717 Warrants to purchase Senior A redeemable convertible preferred stock 358,979 358,979 Warrants to purchase Junior redeemable convertible preferred stock 258,675 222,819 Warrants to purchase common stock 256,411 256,411 Employee stock options 5,291,791 5,055,505 Total 31,477,391 31,205,249

Preferred stock

Preferred stock	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Preferred Stock [Abstract]
Preferred stock	8. Preferred stock Upon completion of the IPO on July 22, 2019, all of the Company’s then outstanding shares of Senior Preferred and Junior Preferred stock automatically converted into an aggregate of 25,311,515 shares of common stock and all of the Company’s then outstanding 42,560,530 shares of redeemable preferred stock were cancelled. As of October 31, 2019, there were no shares of convertible or redeemable preferred stock issued and outstanding. In connection with the IPO, the Company’s Amended and Restated Certificate of Incorporation became effective, which authorized 20,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. Preferred stock dividends of $14,955 were paid in connection with the IPO.	7. Preferred stock The number of outstanding shares and amount of preferred stock are as follows: January 31, 2018 2019 Shares Amount Shares Amount Senior redeemable convertible preferred stock (Senior A) 13,674,365 $ 57,022 13,674,365 $ 79,311 Senior redeemable convertible preferred stock (Senior B) 9,197,142 43,962 9,197,142 51,872 Senior Preferred 22,871,507 100,984 22,871,507 131,183 Junior convertible preferred stock 32,746,041 32,746 32,746,041 32,746 Redeemable preferred stock 42,560,530 42,561 42,560,530 42,561 Total 98,178,078 $ 176,291 98,178,078 $ 206,490 (a) Redeemable preferred stock On October 14, 2014 the Company issued 13,674,365 shares of Senior A Preferred at $2.1939 per share (the “Senior A Preferred Original Issue Price”) for total proceeds of approximately $30,000 and, prior thereto, effected a recapitalization of the previously outstanding Series A-D A-D On October 27, 2017 the Company issued 4,598,571 shares of Senior B Preferred at $3.6968 per share (the “Senior B Preferred Original Issue Price”) for total proceeds of approximately $17,000. On November 29, 2017, the Company issued an additional 4,598,571 shares of Senior B Preferred at the Senior B Preferred Original Issue Price for additional total proceeds of approximately $17,000. Total issuance costs were $1,541. The holders of the Preferred Stock have rights, preferences and privileges as follows: (b) Liquidation In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or the occurrence of a deemed liquidation event, the holders of shares of Senior Preferred then outstanding are entitled to be paid out of the assets of the Company that are available for distribution to its stockholders before any payment would be made to the holders of Junior Preferred, Redeemable Preferred and Common Stock, an amount per share equal to the Senior B Preferred Original Issue Price (in the case of the Senior B Preferred) and the Senior A Preferred Original Issue Price (in the case of the Series A Preferred), together with any accrued and unpaid Accruing Dividends (as defined below) (as adjusted for any excess Participating Amount, as defined below) and any other dividends declared but unpaid thereon (the aggregate amount per share payable to a holder of a share of Senior Preferred pursuant to this sentence is hereinafter referred to as the “Senior Preferred Liquidation Amount”). Upon the completion of the distribution required to the Senior Preferred, the holders of shares of Junior Preferred and Redeemable Preferred then outstanding are entitled to be paid out of the remaining assets of the Company available for distribution to its stockholders on a pari passu Upon the completion of the distribution required to the holders of Senior Preferred, Junior Preferred and Redeemable Preferred, the remaining assets would be distributed pro rata among the holders of Common Stock based on the number of shares of Common Stock held by each such holder. For purposes of determining the amount each holder of Senior Preferred, Junior Preferred or Redeemable Preferred would be entitled to receive as a result of a liquidation, dissolution or winding up of the Company or a deemed liquidation event, each such holder of shares of Senior Preferred or Junior Preferred would be deemed to have converted (regardless of whether such holder actually converted) such holder’s shares of such series into shares of Common Stock (and tendered to the Company any shares of Redeemable Preferred held by such holder for no consideration) immediately prior to such liquidation, dissolution or winding up, or deemed liquidation event if, as a result of an actual conversion, such holder would receive in respect of such series, in the aggregate, an amount (plus, solely in the case of the Senior Preferred, an amount equal to any accrued and unpaid Accruing Dividends, subject to adjustment as described below) greater (such greater amount, the “Participating Amount”) than the aggregate amount that would be distributed to such holder for such series in respect of the Senior Preferred Liquidation Amount, Junior Preferred Liquidation Amount or Redeemable Preferred Liquidation Amount of such series, as described above. For the avoidance of doubt, if any such holder would be deemed to have converted shares of Senior Preferred or Junior Preferred into Common Stock because such holder would receive a greater amount as a result of such conversion, then such holder would not be entitled to receive any per share distributions in respect of the Senior Preferred Liquidation Amount, Junior Preferred Liquidation Amount or Redeemable Preferred Liquidation Amount, as applicable, as described above (other than, with respect to holders of Senior Preferred, any accrued and unpaid Accruing Dividends, subject to adjustment as described below). (c) Conversion The “Senior A Conversion Price” shall mean an amount equal to the Senior A Preferred Original Issue Price, the “Senior B Conversion Price” shall mean an amount equal to the Senior B Preferred Original Issue Price, the “Junior Conversion Price” shall mean an amount equal $1.66 per share, and the “Conversion Price” shall mean, the Senior A Conversion Price, the Senior B Conversion Price or the Junior Conversion Price, as applicable. The Senior A Conversion Price, Senior B Conversion Price and/or Junior Conversion Price may be adjusted upon the occurrence of certain events as set forth in the Company’s certificate of incorporation. Each share of Senior A Preferred is convertible into such number of fully paid and non-assessable non-assessable Each share of Junior Preferred is convertible into such number of fully paid and non-assessable The conversion ratio for the Senior Preferred and Junior Preferred is 1:0.4551 at January 31, 2018 and 2019. The Senior Preferred and Junior Preferred are automatically convertible into Common Stock upon a qualified initial public offering, as defined (a “Qualified IPO”). Upon a Qualified IPO, the holders of Senior Preferred are also entitled to accrued but unpaid Accruing Dividends. Upon an automatic conversion of the Junior Preferred in connection with a Qualified IPO, all shares of Redeemable Preferred will be automatically extinguished and cancelled. (d) Voting Each holder of outstanding shares of Senior Preferred and Junior Preferred is entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Senior Preferred or Junior Preferred, as applicable, are convertible and vote together with the holders of Common Stock as a single class. In addition, the Preferred Stock has certain special protective voting rights as described in the Company’s certificate of incorporation. The holders of the Redeemable Preferred are not entitled to vote in respect of such shares other than as required by law.

Dividends

Dividends	12 Months Ended
	Jan. 31, 2019
Text Block [Abstract]
Dividends	7. Dividends The Common Stock, Junior Preferred and the Redeemable Preferred do not accrue any dividends. From and after the date of the issuance of a share of Senior A Preferred, dividends accrue at the rate per annum of 8% of the Senior A Preferred Original Issue Price on each such share of Senior A Preferred (the “Accruing Dividends”). From and after the date of the issuance of a share of Senior B Preferred, dividends accrue at the rate per annum of 8% of the Senior B Preferred Original Issue Price on each such share of Senior B Preferred. Accruing Dividends accrue, whether or not declared, compound annually and are cumulative; provided, however, that the Accruing Dividends are subject to adjustment as set forth below. The Accruing Dividends are payable only upon occurrence of certain events, including a voluntary or involuntary liquidation, dissolution or winding up of the Company, a deemed liquidation event, a redemption of the Senior Preferred or upon a Qualified IPO of the Company. The Accruing Dividends payable may be adjusted as follows: (a) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be greater than or equal to 4.5 times the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then no Accruing Dividends would be paid with respect to such share of Senior Preferred; (b) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be less than or equal to 3.5 times the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then 100% of the Accruing Dividends would be paid with respect to such share of Senior Preferred; and (c) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be greater than 3.5 times and less than 4.5 times (such applicable multiple, the “Special Multiple”) the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then the amount of the aggregate Accruing Dividends paid with respect to such share of Senior Preferred would equal the product of (a) the Applicable Difference and (b) an amount equal to 100% of the Accruing Dividends (prior to giving effect to any adjustment). The “Applicable Difference” means an amount equal to the difference between 4.5 times and the Special Multiple. Cumulative undeclared dividends totaled $8,997 and $14,837 at January 31, 2018 and January 31, 2019, respectively. (e) Redemption Shares of Senior Preferred shall be redeemed by the Company out of funds lawfully available therefore at a price per share equal to the greater of (i) the fair market value of the Senior Preferred as of the redemption date and (ii) the Senior Preferred Original Issue Price, together with any other dividends declared but unpaid thereon, and any Accruing Dividends accrued by unpaid thereon (the “Senior Preferred Redemption Price”), in three annual installments commencing 60 days after receipt by the Company at any time on or after October 27, 2021, from the holders of at least a majority of the then outstanding shares of Senior Preferred, of written notice requesting redemption of all (but not less than all) shares of Senior Preferred. In addition, if at any time the Company (i) becomes legally insolvent or (ii) defaults on any outstanding debt which is material to the Company which such default results in an acceleration of such debt, the Board of Directors shall cause the Company to take all reasonable action to redeem the Senior Preferred at the Senior Preferred Redemption Price within one hundred and twenty (120) days after written notice from the holders of at least a majority of the then outstanding shares of Senior Preferred. Effective only after the shares of Senior Preferred have been redeemed or with the express written consent of the holders of a majority of the then outstanding shares of Senior Preferred, shares of Junior Preferred and Redeemable Preferred shall be redeemed by the Company out of funds lawfully available therefor at a price per share equal to the Junior Preferred Original Issue Price, together with any other dividends declared but unpaid thereon, or Redeemable Preferred Original Issue Price, respectively, in three annual installments commencing 60 days after receipt by the Company at any time on or after October 27, 2021, from the holders of at least a majority of the then outstanding shares of Junior Preferred, of written notice requesting redemption of all (but not less than all) shares of Junior Preferred and Redeemable Preferred. The carrying values of the Senior Preferred are being accreted to their redemption values through January 31, 2019. The redemption values of the Senior Preferred are based on the estimated fair values at January 31, 2018 and 2019 because they are estimated to be greater than the original issuance price plus accrued dividends.

Equity-based compensation

Equity-based compensation	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Share-based Payment Arrangement [Abstract]
Equity-based compensation	9. Equity-based compensation (a) Stock options In 2006, the Board of Directors adopted the Company’s 2006 Stock Option Plan (the “2006 Plan”), which provided for the issuance of options to purchase up to 151,548 shares of the Company’s common stock to officers, directors, employees, and consultants. Over the years, the Company amended the plan to increase the shares available for issuance. On October 14, 2014, the Company increased the number of shares available for issuance under the 2006 Plan to 4,424,986. The 2006 Plan expired in August 2017. In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended) (the “2018 Plan”), which currently provides for the issuance of additional options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the “2019 Plan”), which replaced the 2018 Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee to make equity-based incentive awards to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this Plan is 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance will automatically increase on February 1, 2020 and each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). Options granted under the plans has a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year Effective July 2019, all available shares from expired, terminated, or forfeited awards that remained under the 2006 Plan or the 2018 Plan will be available for grant under the 2019 Plan. In June 2019, the Board of Directors also adopted the Company’s 2019 Employee Stock Purchase Plan (the “ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP is limited to 855,873 shares. The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The Company historically has been a private company and lacked company-specific historical and implied volatility information for shares. Accordingly, expected volatility is based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in SEC Staff Accounting Bulletin (“SAB”) 107 to estimate the expected life of stock options. Forfeitures are recorded when they occur. The risk-free rate is based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. The weighted average assumptions are provided below. For the nine months ended October 31, October 31, Risk-free interest rate 2.83% 2.18% Expected dividends None None Expected term (in years) 6.25 6.25 Volatility 45.00% 45.15% Weighted average fair market value of grants $ 3.72 $ 4.99 Stock option activity for the nine months ended October 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding—January 31, 2019 5,055,505 $ 2.45 Granted in the nine months ended October 31, 2019 1,230,382 $ 8.78 Exercised (111,515 ) $ 3.98 Forfeited and expired (53,627 ) $ 3.38 Outstanding and expected to vest—October 31, 2019 6,120,745 $ 3.67 6.35 $ 140,339 Exercisable—October 31, 2019 4,197,481 $ 2.09 4.84 $ 103,178 Amount vested in the nine months ended October 31, 2019 621,206 $ 4.03 As of October 31, 2019, there are 2,129,560 shares available for future grant pursuant to the newly adopted 2019 Plan as well as an additional 855,873 shares available for future grant pursuant to the newly adopted ESPP. The aggregate intrinsic value represents the total pre-tax in-the-money For the nine months ended October 31, 2018 and 2019, the Company recorded stock-based compensation expense for stock options of $950 and $2,051, respectively. As of October 31, 2019, there is $6,975 of total unrecognized compensation cost related to stock options issued October to employees that is expected to be recognized over a weighted-average term of 2.98 years. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. Incremental expense associated with the modification of stock options during the nine months ended October 31, 2019 was $173. (b) Restricted stock units On March 25, 2019 and June 20, 2019, the Company issued 390,794 and 58,589 stock units, respectively, to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to the time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition is based on a sale of the Company or an IPO, as defined. The restricted stock units expire seven years from the grant date. Upon completion of the Company’s IPO in July 2019, the Company immediately recognized the fair value of the vested units with the unvested portion recognized over the remaining service period. In addition, in August 2019, the Company approved allowing executive officers the ability to elect to receive all or a portion of the bonus (based on its target bonus opportunity for the last half of the fiscal year) in the form of restricted stock units instead of cash. For such executive officers that elected to receive restricted stock units, such award was granted immediately after such election with a value equal to the portion of the target bonus opportunity that the executive officer elected not to receive in cash, and such award vests based on the achievement of the Company’s pre-defined performance targets. Further, such executive officer may earn up to 200% of the target number of restricted stock units based on actual performance, provided that certain stipulations are met. The Company issued 4,873 time-based restricted stock units and 72,126 performance-based restricted stock units in August 2019. These time-based restricted stock units are subject to the same four-year vesting period as the previously granted units. The performance-based units, issued to key employees, are subject to the Company’s pre-defined targets. These performance-based units will vest over a six month period. Restricted stock unit activity for the nine months ended October 31, 2019 are as follows: Restricted stock units Balance—January 31, 2019 20,164 Granted 526,382 Forfeited (22,185 ) Balance—October 31, 2019 524,361 For the nine months ended October 31, 2019, the Company recognized $1,781, in restricted stock unit compensation expense, with $3,779 remaining of total unrecognized compensation costs related to these awards as of October 31, 2019.	8. Stock options In 2006, the Board of Directors adopted the Company’s 2006 Stock Option Plan, which provided for the issuance of options to purchase up to 151,548 shares of the Company’s common stock to officers, directors, employees, and consultants. Over the years, the Company has amended the plan to increase the shares available for issuance. On October 14, 2014, the Company increased the number of shares available for issuance under the 2006 plan to 4,424,986. The 2006 Stock Option Plan expired on August 2017. In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended) (see note 17), which currently provides for the issuance of additional options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. Options granted under the plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The assumptions are provided below. Expected volatility was based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in SAB 107 to estimate the expected life of stock options. Forfeitures are recorded when they occur. The risk-free rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. January 31, 2018 2019 Risk-free interest rate 2.59% 2.81% Expected dividends None None Expected term (in years) 6.25 6.25 Volatility 41.00% 40.00% Weighted average fair value of grants $ 2.07 $ 3.47 Stock option activity for fiscal 2018 and fiscal 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding—February 1, 2017 4,295,364 $ 1.53 Granted during the year 1,295,132 $ 4.71 Exercised (143,600 ) $ 1.03 Forfeited and expired (155,105 ) $ 2.36 Outstanding—January 31, 2018 5,291,791 $ 2.30 Exercisable—January 31, 2018 3,260,333 $ 1.36 Amount vested in fiscal 2018 684,322 $ 1.91 Outstanding—February 1, 2018 5,291,791 $ 2.30 Granted during the year 262,566 $ 4.71 Exercised (316,063 ) $ 1.15 Forfeited (182,789 ) $ 3.72 Outstanding and expected to vest—January 31, 2019 5,055,505 $ 2.45 6.40 $ 28,217 Exercisable—January 31, 2019 3,658,339 $ 1.76 5.48 $ 23,072 Amount vested in fiscal 2019 736,028 $ 3.27 As of January 31, 2019, there are 42,213 shares available for future grant pursuant to the plan. The aggregate intrinsic value represents the total pre-tax in-the-money For fiscal 2018 and fiscal 2019, the Company recorded stock-based compensation expense of $805 and $1,447,199, respectively. As of January 31, 2019, there is $3,195 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 1.98 years. During fiscal 2019, the Company recorded stock-based compensation of $7 related to restricted stock issued in connection with the Vital Score acquisition (Note 16). As of January 31, 2019, there is $155 of total unrecognized compensation cost related to these awards. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.

Stock warrant liabilities

Stock warrant liabilities	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Warrant [Member]
Stock warrant liabilities	10. Stock warrants As of January 31, 2019 and October 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase January 31, October 31, Exercise price Expiration Senior A Preferred 116,232 — $ 2.19 October 1, 2021 Senior A Preferred 672,560 — $ 3.00 November 1, 2026 Junior Preferred 489,605 — $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) 1,636,641 — Common stock 166,952 — $ 2.02 October 21, 2025 Common stock 89,459 — $ 3.49 November 1, 2026 Common stock — 75,137 $ 8.02 February 28, 2029 Common stock (converted from preferred stock warrants) — 153,041 $ 6.59 November 1, 2026 Total common stock (equity-classified) 256,411 228,178 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance—January 31, 2019 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (760,305 ) (1,636,641 ) Balance—October 31, 2019 228,178 — The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants nine months ended October 31, 2019 3,307 Conversion of convertible preferred stock warrants (8,805 ) Balance at October 31, 2019 $ — Upon the closing of the IPO in July 2019, the Company’s outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase an aggregate of 581,798 shares of common stock. Upon the conversion, the Company reclassified the warrants to equity and recorded the then current value of the warrant liability on the date of reclassification to additional paid-in-capital. In July and September 2019, the existing common stock warrant holders completed the cashless exercise of the warrants, resulting in the issuance of 256,411 and 75,137 shares of common stock, respectively, whereby 25,919 and 22,114 shares of common stock, respectively, were withheld by the Company to pay for the exercise price of the warrants, and 230,492 and 53,023 shares of common stock were issued, respectively.	9. Stock warrant liabilities As of January 31, 2018 and 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase 2018 2019 Exercise Expiration Senior A Preferred 116,232 116,232 $ 2.19 October 1, 2021 Senior A Preferred 672,560 672,560 $ 3.00 November 1, 2026 Junior Preferred 489,605 489,605 $ 0.01 September 5, 2020 Junior Preferred 32,590 — $ 1.00 February 2, 2018 Junior Preferred 46,197 — $ 1.00 April 15, 2018 Redeemable Preferred 358,244 358,244 $ 0.01 September 5, 2020 Redeemable Preferred 23,846 — $ 0.73 February 2, 2018 Redeemable Preferred 33,802 — $ 0.73 April 15, 2018 Total preferred stock (liability-classified) 1,773,076 1,636,641 Common stock 166,952 166,952 $ 2.02 October 21, 2025 Common stock 89,459 89,459 $ 3.49 November 1, 2026 Total common stock (equity-classified) 256,411 256,411 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance at February 1, 2017 256,411 1,813,076 Exercised — (40,000 ) Balance—January 31, 2018 256,411 1,773,076 Forfeited — (136,435 ) Balance—January 31, 2019 256,411 1,636,641 The following table is a reconciliation of the warrant liability measured at fair value: Warrant liability Balance at February 1, 2017 $ 2,870 Exercised (28 ) Change in fair value of stock warrants during year 598 Balance at January 31, 2018 $ 3,440 Change in fair value of stock warrants during year 2,058 Balance at January 31, 2019 $ 5,498

Fair value measurements

Fair value measurements	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair value measurements The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The Company uses certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company recognizes all derivatives on the balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency contracts as of January 31, 2019 and October 31, 2019 was a liability of $143 and $24, respectively, which are included in Accounts payable on the accompanying balance sheet. The fair value of the foreign currency contracts are considered Level 2 in the fair value hierarchy as of January 31, 2019 and October 31, 2019, respectively. Warrant Liability—The warrant liability is related to the warrants to purchase shares of preferred stock (See Note 10). Upon the closing of the IPO in July 2019, the warrants to purchase the Company’s convertible preferred stock were either converted into warrants to purchase common stock or subject to the cashless exercise into shares of common stock. As a result, the warrant liability was remeasured immediately prior to the closing date of the IPO and reclassified to stockholders’ equity (deficit). The Company used the Black-Scholes option-pricing model, which incorporated weighted-average inputs and assumptions, to value the warrant liability as of January 31, 2019 and as of the date of conversion. As of January 31, 2019, the warrant liability was valued at $5,498 as a non-current The Black-Scholes method and the following weighted-average inputs and assumptions were utilized to determine the fair value of the warrants as of January 31, 2019, pre-stock January 31, 2019 Series A Junior Redeemable preferred Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6% 2.5% 2.5% Expected volatility 45.1% 45.1% 45.1% Dividend yield 0.0% 0.0% 0.0% The Black-Scholes Method and the following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior preferred Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9% 1.9% Expected volatility 45.9% 45.9% Dividend yield 0.0% 0.0% As the Company refinanced all of its debt on February 28, 2019 (see Note 6), it believes that the face value of its outstanding debt at January 31, 2019 and October 31, 2019 approximates fair value. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the nine months ended October 31, 2018 and 2019. The Company’s cash and cash equivalents includes money market funds which is measured at fair value. The Company consider these investments within Level 1 of the fair value hierarchy.	10. Fair Value Measurements The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximated fair value due to the short-term nature of these instruments. The Company uses certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company recognizes all derivatives on the balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency contracts at January 31, 2018 was an asset of $82, which is included in Other assets on the accompanying balance sheet. The fair value of its foreign currency contracts at January 31, 2019 was a liability of $143, which is included in Accounts payable on the accompanying balance sheet. The fair value of the foreign currency contracts are considered Level 2 in the fair value hierarchy in fiscal 2018 and 2019. Warrant Liability—The carrying value of the stock warrant liability is adjusted to fair value each reporting period. The Black-Scholes method and the following weighted-average inputs and assumptions was utilized to determine the fair value of the warrants as of January 31, 2018 and 2019: January 31, 2018 Series A Preferred Junior Redeemable Estimated fair value of preferred stock $ 4.17 $ 2.38 $ 0.79 Exercise price $ 2.88 $ 0.15 $ 0.11 Remaining term (in years) 8.01 2.25 2.25 Risk-free interest rate 2.4% 1.8% 1.8% Expected volatility 37.8% 38.8% 38.8% Dividend yield 0.0% 0.0% 0.0% January 31, 2019 Series A Preferred Junior Redeemable Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6% 2.5% 2.5% Expected volatility 45.1% 45.1% 45.1% Dividend yield 0.0% 0.0% 0.0% The Company refinanced all of its debt on February 28, 2019 (see Note 5) and believes that the face values of its outstanding debt at January 31, 2019 therefore approximate fair value. The changes in Level 3 warrant liability for the years ended January 31, 2018 and 2019 are reflected in Note 9. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the years ended January 31, 2018 and 2019.

Commitments and contingencies

Commitments and contingencies	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	12. Commitments and contingencies (a) Operating and capital leases The Company leases its office premises in New York, North Carolina, and Ottawa under operating leases which expire on various dates through August 2022. The Company recognizes rent expense under such arrangements on a straight-line basis. Rent expense under such operating leases amounted to $1,350 and $1,373 for the nine months ended October 31, 2018 and 2019, respectively. As of October 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining three months) $ 443 Year ending January 31, 2021 1,824 2022 819 2023 464 Total operating lease payments $ 3,550 During the nine months ended October 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining three months) $ 611 Year ending January 31, 2021 2,404 2022 1,621 2023 200 Total capital lease payments $ 4,836 Less amounts representing interest (452) Total capital lease payments, net of interest 4,384 Less current portion (2,413) Total capital lease payments, net of interest and current portion $ 1,971 Interest expense related to capital leases was $190 and $215 for the nine months ended October 31, 2018 and 2019, respectively. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.	11. Commitments and contingencies (a) Operating and Capital leases The Company leases its office premises in New York, North Carolina and Ottawa under operating leases which expire on various dates through August 2022. The Company recognizes rent expense under such arrangements on a straight-line basis. Rent expense under such operating leases amounted to $1,640 and $1,795 for the years ended January 31, 2018 and 2019, respectively. As of January 31, 2019, the aggregate minimum net rental payments for non-cancelable January 31, 2020 $ 1,736 2021 1,751 2022 745 2023 225 $ 4,457 During fiscal year ended January 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 January 31, 2020 $ 2,282 2021 1,767 2022 984 $ 5,033 Less: Amounts representing interest (763 ) $ 4,270 Less: Current portion (1,869 ) $ 2,401 The Company has also entered into operating equipment and software leases. The leases are for a 36 month period beginning February 2012. Interest expense related to capital leases was $211 and $290 for the years ended January 31, 2018 and 2019, respectively. (b) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued any liabilities related to such obligations in our financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require us, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (c) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.

Income taxes

Income taxes	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	13. Income taxes The effective tax rate is 0% and 0% in the nine months ended 31, 2018 and 2019, respectively. The difference between the U.S. Statutory rate of 21% and the effective tax rate is primarily due to the change in valuation allowance. The Company has recorded a full valuation allowance against its deferred tax assets at January 31, 2019 and October 31, 2019.	12. Income taxes The Company’s loss before income taxes was primarily generated in the United States for fiscal 2018 and fiscal 2019. The effective tax rate is 0% in both of the years ended fiscal 2018 and fiscal 2019. The difference between the U.S. statutory rate of 21.0% and the effective tax rate is primarily due to the change in valuation allowance. The tax effects of temporary differences and carryforwards that give rise to deferred tax assets and deferred tax liabilities at January 31, 2018 and 2019, are as follows: January 31, Deferred tax assets 2018 2019 Net operating losses $ 27,464 $ 29,068 Stock options 274 516 Other 248 276 Vacation 104 111 Reserve for bad debts 55 73 Disallowed interest expense — 415 Depreciation — 278 Total Deferred tax assets $ 28,145 $ 30,737 Deferred tax liability—depreciation (437 ) — Deferred contract acquisition costs (607 ) (849 ) Total net deferred tax asset $ 27,101 $ 29,888 Less valuation allowance (27,101 ) (29,888 ) Net deferred tax asset $ — $ — The Company has accumulated a Federal net operating loss carryforward of approximately $93,000 and $100,000 as of January 31, 2018 and 2019, respectively. This carryforward will begin to expire in 2029. Certain research and development tax credits totaling approximately $25 will begin to expire in 2032. In assessing the realizability of the net deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company believes that it is more likely than not that the Company’s deferred income tax asset associated with its net operating losses will not be realized. As such, there is a full valuation allowance against the net deferred tax assets as of January 31, 2018 and 2019. The valuation allowance increased by approximately $2,800 during fiscal 2019 due primarily to the generation of net operating losses. Under the Tax Reform Act of 1986 (the “Act”), the net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes, as defined by the Act, have occurred since inception. The Company records unrecognized tax benefits as liabilities related to its operations in foreign jurisdictions in accordance with ASC 740 and adjusts these liabilities when its judgement changes as a result of the evaluation of new information not previously available. Due to net operating loss and tax credit carry forwards that remain unutilized, income tax returns for tax years from inception through 2018 remain subject to examination by the taxing jurisdictions. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act significantly revises the existing tax law by, among other things, lowering the U.S. corporate income tax rate from 35% to 21% beginning in 2018. The Company reviewed and incorporated the impact of the Tax Act in its tax calculations and disclosures. The Tax Act did not have a significant impact on the Company’s financial statements for the year ended January 31, 2019.

Net loss per share and unaudite

Net loss per share and unaudited pro forma net loss per share attributable to common stockholders	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Earnings Per Share [Abstract]
Net loss per share and unaudited pro forma net loss per share attributable to common stockholders	14. Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Nine months ended October 31, 2018 2019 Numerator: Net loss $ (9,983 ) $ (16,625 ) Preferred stock dividend paid — (14,955 ) Accretion of redeemable convertible preferred stock to redemption value (20,962 ) (56,175 ) Net loss attributable to common stockholders $ (30,945 ) $ (87,755 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,176,833 15,007,247 Net loss attributable to common stockholders $ (26.30 ) $ (5.85 ) The Company’s potential dilutive securities, which include Convertible Preferred, stock options, restricted stock units and outstanding warrants to purchase shares of common and preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: October 31, October 31, Redeemable convertible preferred stock (as-converted 25,311,535 - Stock options to purchase common stock and restricted stock units 5,094,108 6,645,106 Warrants to purchase convertible preferred stock 581,798 - Warrants to purchase common stock 256,411 228,178 31,243,852 6,873,284	13. Net loss per share and unaudited pro forma net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended January 31, 2018 2019 Numerator: Net loss $ (18,192 ) $ (15,062 ) Accretion of Convertible Preferred to redemption value (19,981 ) (30,199 ) Net loss attributable to common stockholders $ (38,173 ) $ (45,261 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,538,600 1,844,929 Net loss attributable to common stockholders, basic and diluted $ (24.81 ) $ (24.53 ) The Company’s potential dilutive securities, which include Convertible Preferred, stock options and outstanding warrants to purchase shares of common and preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended January 31, 2018 2019 Convertible Preferred (as-converted 25,311,535 25,311,535 Stock options to purchase common stock 5,291,791 5,055,505 Warrants to purchase Convertible Preferred 617,654 581,798 Warrants to purchase common stock 256,411 256,411 Total 31,477,391 31,205,249 (b) Unaudited pro forma net loss per share The unaudited pro forma basic and diluted net loss per share attributable to common stockholders for fiscal 2019 gives effect to the adjustments arising upon the closing of the initial public offering. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited basic and diluted pro forma net loss per share attributable to common stockholders does not include the effects of the accretion of Convertible Preferred to redemption value because the calculation assumes that the conversion of Convertible Preferred into common stock occurred on February 1, 2018. The unaudited pro forma basic and diluted weighted-average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders for fiscal 2019 gives effect to the conversion upon the initial public offering of all outstanding shares of Convertible Preferred as of January 31, 2019, into 25,311,535 shares of common stock as if the conversion had occurred on February 1, 2018, assuming a Qualified IPO, as well as the automatic cashless exercise of a warrant to purchase 116,232 shares of Senior A into 36,959 shares of common stock, based on an assumption that the fair market value of the Company’s common stock for purposes of automatic exercise under the warrant will be equal to the assumed initial public offering price of $16.00 per share. The unaudited pro forma basic and diluted net loss per share also gives effect to 1,129,539 shares of common stock for which the proceeds would be necessary to pay the dividend amount of $18,073 to the holders of Senior Preferred Stock based on the assumed initial public offering price of $16.00 per share. Unaudited pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended Numerator: Net loss attributable to common stockholders $ (45,261 ) Pro forma adjustments: Accretion of preferred stock 30,199 Change in fair value of warrant 177 Pro Forma net loss attributable to common stockholders, basic and diluted $ (14,885 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,844,929 Pro Forma adjustments: Assumed conversion of preferred stock 25,311,535 Cashless exercise of warrants 36,959 Share assumed issued to pay dividends 1,129,539 Pro Forma weighted-average common shares outstanding, basic and diluted 28,322,962 Pro Forma net loss per share attributable to common stockholders, basic and diluted $ (0.53 )

Retirement savings plan

Retirement savings plan	12 Months Ended
	Jan. 31, 2019
Retirement Benefits [Abstract]
Retirement savings plan	14. Retirement savings plan On February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre-tax

Related party transactions

Related party transactions	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Related Party Transactions [Abstract]
Related party transactions	15. Related party transactions The Company recognized revenue totaling approximately $3,693 and $4,098 from an affiliate of a stockholder of the Company for the nine months ended October 31, 2018 and 2019, respectively. Accounts receivable from the affiliate totaled approximately $598 and $1,277 as of January 31, 2019 and October 31, 2019, respectively.	15. Related party transactions The Company recognized revenue totaling approximately $4,882 and $5,181 from an affiliate of a stockholder of the Company during the years ended January 31, 2018 and 2019, respectively. Accounts receivable from the affiliate totaled approximately $526 and $598 as of January 31, 2018 and 2019, respectively.

Acquisition

Acquisition	12 Months Ended
	Jan. 31, 2019
Business Combinations [Abstract]
Acquisition	16. Acquisition On December 4, 2018, the Company entered into an asset purchase agreement with Vital Score, Inc. (“Vital Score”) to acquire all of the assets, and assumed certain of the liabilities, of Vital Score. The acquisition of Vital Score expanded the Company’s clinical and patient activation offerings and deepened its capabilities in motivational science. The acquisition consideration was comprised of cash consideration consisting of (i) $1,540 with $1,190 payable upon the closing of the acquisition and $350 payable on the first anniversary; and (ii) 40,327 shares of common stock issued to the two principals of Vital Score which vest 50% at closing and 50% in four equal annual installments beginning on the one-year The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration $ 1,540 Common stock issued (20,164 shares at $8.03 per share) 162 Total fair value of acquisition consideration $ 1,702 The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Property and equipment $ 5 Acquired technology 490 Customer relationships 980 Goodwill 250 Total assets acquired $ 1,725 Accounts payable (23 ) Total purchase price $ 1,702 The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimated fair values. The identifiable intangible assets principally included acquired technology and customer relationships, both of which are subject to amortization on a straight-line basis and are being amortized over 5 and 7 years, respectively. The weighted average amortization period for acquired intangible assets as of the date of acquisition is 5.8 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Vital Score. The fair value of the acquired technology was estimated using the cost to replace method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each client grouping. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is deductible for income tax purposes. The Company believes the goodwill related to the acquisition was a result of providing the Company a complementary service offering that will enable the Company to leverage its services with existing and new clients. The goodwill is deductible for income tax purposes. Revenue from Vital Score is primarily comprised of fees from customers using its Motivational Indexing Product. Revenue for these services and the related costs are recognized each month as performance obligations are satisfied and costs are incurred, and are included in subscription and related services and cost of revenues (excluding depreciation and amortization), respectively, in the statements of operations. For the period from December 4, 2018 (date of acquisition) to January 31, 2019, the results of Vital Score are included in the Company’s results and were immaterial. For the year ended January 31, 2018, the unaudited revenues and unaudited net loss of Vital Score were approximately $250 and $455, respectively. For the period from February 1, 2018 through December 4, 2018, the unaudited revenues and unaudited net loss of Vital Score were approximately $100 and $600, respectively.

Subsequent events

Subsequent events	12 Months Ended
	Jan. 31, 2019
Subsequent Events [Abstract]
Subsequent events	17. Subsequent events On February 28, 2019, the Company entered into an amended and restated loan and security agreement. See Note 5. On March 25, 2019, the Board of Directors approved an increase in the number of shares authorized for issuance under the 2018 Stock Option Plan to 3,048,490. Additionally, the Company issued 390,794 restricted stock units to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to the time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition is based on a sale of the Company or an IPO, as defined. The restricted stock units expire in March 2026. The Company also issued options to purchase 962,596 shares of common stock to employees and directors at an exercise price of $8.03 per share. The options vest 25% per year over a four year period and expire in March 2029. The Company has evaluated subsequent events from the balance sheet date through April 17, 2019, the date at which the financial statements were available to be issued, and determined there are no other items requiring disclosure.

Revenue

Revenue	9 Months Ended
	Oct. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital patient engagement revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The amount of subscription and related services revenues recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $3,388 and $4,462 for the nine months ended October 31, 2018 and 2019, respectively. Contract balances The following table represents a rollforward of contract assets and contract liabilities: Contract assets (unbilled receivable) Contract liabilities (deferred revenue) January 31, 2019 $ 636 $ 6,488 Amount transferred to receivables from contract assets (576 ) — Contract asset additions 918 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (11,168 ) Increases due to invoicing prior to satisfaction of performance obligations — 10,006 October 31, 2019 $ 978 $ 5,326 Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contract and amortizes these costs over the life of the contracts. Amortization expense totaled $1,179 and $1,465 for the nine months ended October 31, 2018 and 2019, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: January 31, October 31, 2019 2019 Beginning balance $ 2,334 $ 3,194 Additions to deferred contract acquisition costs 2,500 1,414 Amortization of deferred contract acquisition costs (1,640 ) (1,465 ) Ending balance 3,194 3,143 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,673 1,631 Deferred contract acquisition costs, non current 1,521 1,512 Total deferred contract acquisition costs $ 3,194 $ 3,143

Basis of presentation (Policies

Basis of presentation (Policies)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada.	(a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and include the accounts of Phreesia, Inc. and its branch operation in Canada.
Fiscal year	(b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively.	(b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively.
Use of estimates	(a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use	(a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use
Revenue recognition		(b) Revenue recognition The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital marketing revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The Company has adopted Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, The Company accounts for revenue from contracts with customers by applying the requirements of Topic 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type. Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare provider organizations that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (“PhreesiaPads”) and on-site non-cancelable Leases In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Stations), on-site Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees. The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. Life sciences The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to targeted patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by revenue source on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees and digital marketing solutions sold to life sciences companies. In addition, all of the Company’s revenue is derived from customers in the United States. Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either: contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). Contract balances Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from its subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract February 1, 2017 $ 78 $ 5,605 Contract asset additions 96 — Amount transferred to receivables from contract assets (68 ) — Increases due to invoicing prior to satisfaction of performance obligations — 2,890 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (3,609 ) January 31, 2018 $ 107 $ 4,886 Contract asset additions 615 — Amount transferred to receivables from contract assets (86 ) — Increases due to invoicing prior to satisfaction of performance obligations — 5,900 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (4,298 ) January 31, 2019 $ 636 $ 6,488 Cost to obtain a contract The Company capitalizes sales commissions paid to internal sales personnel that are incremental to the acquisition of customer contracts. These costs are recorded as deferred contract acquisition costs on the accompanying balance sheets. The Company determines whether costs should be deferred based on its sales compensation plans and if the commissions are incremental and would not have occurred absent the customer contract. Sales commission for subscription and related services are recorded when earned by our sales team. The majority of our sales commissions are considered to be costs of obtaining our customer contracts and as a result are capitalized and then amortized over a period of benefit that the Company has estimated to be three years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,389 and $1,640 for the fiscal years ended January 31, 2018 and 2019, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: January 31, 2018 2019 Beginning balance $ 1,950 $ 2,334 Additions to deferred contract acquisition costs 1,773 2,500 Amortization of deferred contract acquisition costs (1,389 ) (1,640 ) Ending balance $ 2,334 $ 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,640 1,673 Deferred contract acquisition costs, non current 694 1,521 Total deferred contract acquisition costs $ 2,334 $ 3,194
Cost of Revenue		(c) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Platform such as hosting fees, certain fees paid to various third party partners for the use of their technology, and personnel expenses for implementation and technical support. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
Payment processing expense		(d) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks and that are ultimately paid to the card-issuing financial institution, assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways.
Sales and marketing		(e) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $17 and $134 for the fiscal years ended 2018 and 2019, respectively.
Research and development		(f) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use
General and administrative		(g) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation		(h) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Stations (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.
Amortization		(i) Amortization Amortization primarily represents amortization of our capitalized internal-use
Cash and Cash Equivalents		(j) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.
Settlement assets		(k) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one or two business days of the transaction date.
Settlement obligations		(l) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts Receivable		(m) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts based on specific account analysis of at-risk Account receivable also includes unbilled accounts receivable (see Contract Balances).
Property, Plant and Equipment		(n) Property and equipment Property and equipment, including PhreesiaPads, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three and seven years, with the useful lives of leasehold improvements being the shorter of the useful life of the asset or the life of the underlying lease. Maintenance and repair costs are charged to operations as incurred while expenditures for major improvements are capitalized. Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
Capitalized Internal Use Software		(o) Capitalized internal-use The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC Topic 350-40, Intangibles—Goodwill and Other—Internal use software Internal-use internal-use For fiscal 2018 and fiscal 2019, the Company capitalized $5,375 and $5,109, respectively, of costs related to the Phreesia Platform. During the years ended January 31, 2018 and 2019, amortization expense of capitalized internal-use
Business Combinations		(p) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the statement of operations.
Goodwill and Intangible Assets		(q) Goodwill and intangible assets Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, it is necessary to perform the two-step two-step “step-one All other intangible assets associated with purchased intangibles, consisting of customer relationships and acquired technology are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long Lived Assets		(r) Long-lived assets Long-lived assets, such as property and equipment and intangible assets, including capitalized internal-use
Income Tax		(s) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the ASC 740, Accounting for Uncertainty in Income Taxes de-recognition, The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability. The Company determined that there were no unrecognized tax benefits as of January 31, 2018 and 2019. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision (benefit) from income taxes.
Segment Reporting		(t) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the financial statements.
Redeemable Preferred Stock		(u) Redeemable preferred stock All of the Company’s redeemable preferred stock is classified outside of stockholders’ deficit because the shares contain certain redemption features that are not solely within the control of the Company. At the time of issuance, the redeemable preferred stock is recorded at its issuance price, less issuance costs. The carrying values of the Senior Preferred are being accreted to their redemption values at each reporting period, which is equal to the greater of (i) the original issuance price plus unpaid accrued dividends or (ii) the fair value of the Senior Preferred. The Junior Preferred and Redeemable Preferred were accreted to their redemption amount, which is $1.00 per share. The Company records changes in the redemption value of redeemable preferred stock immediately as they occur as if the end of the reporting period was the redemption date for the instrument.
Stock Based Compensation		(v) Stock-based compensation The Company recognizes the grant-date fair value of stock-based awards issued as compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. To date, the Company has not issued awards where vesting is subject to performance or market conditions. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the estimated fair value of the underlying common stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, the most critical of which is the estimated fair value of the Company’s common stock. The estimated fair value of each grant of stock options awarded during the years ended January 31, 2018 and 2019 was determined using the following methods and assumptions: • Estimated fair value of common stock. Valuation of Privately-Held-Company Equity Securities Issued as Compensation • Expected term. Share-Based Payment • Risk-free interest rate. • Expected volatility. • Dividend yield. The inputs and assumptions used to estimate the fair value of stock-based payment awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different inputs and assumptions, the Company’s stock-based compensation expense could be materially different for future awards.
Warrant liability		(w) Warrant liability Warrants to purchase shares of the Company’s redeemable preferred stock are classified as warrant liability on the accompanying balance sheet and recorded at fair value. This warrant liability is subject to re-measurement paid-in
Fair Value of Financial Instruments		(x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under generally accepted accounting principles. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Concentration Risk	(b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the nine months ended October 31.	(y) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of Cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more 10% of total revenues for fiscal 2018 and fiscal 2019.
Deferred Offering Costs		(z) Deferred offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process paid-in
Foreign Currency Transactions		(aa) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured
New accounting pronouncements	(c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight	(bb) New accounting pronouncements JOBS Act accounting election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company has elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently adopted accounting pronouncements In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In May 2017, the FASB issued ASU 2017-09, Scope of Modification Accounting In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments zero-coupon In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting re-measure 2018-07 Recent accounting pronouncement not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13”). 2018-13 In February 2016, the FASB issued ASU 2016-02, Leases right-of-use use-of-hindsight
Unaudited interim financial statements	(c) Unaudited interim financial statements The accompanying financial statements and the related footnote disclosures are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s interim financial position as of October 31, 2019 and the results of its operations and its cash flows for the periods ended October 31, 2018 and 2019. The results for the interim periods are not necessarily indicative of results to be expected for the full year, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited financial statements and accompanying notes for the year ended January 31, 2019.

Revenue (Tables)

Revenue (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Rollforward of contract assets and contract liabilities	The following table represents a rollforward of contract assets and contract liabilities: Contract assets (unbilled receivable) Contract liabilities (deferred revenue) January 31, 2019 $ 636 $ 6,488 Amount transferred to receivables from contract assets (576 ) — Contract asset additions 918 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (11,168 ) Increases due to invoicing prior to satisfaction of performance obligations — 10,006 October 31, 2019 $ 978 $ 5,326	The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract February 1, 2017 $ 78 $ 5,605 Contract asset additions 96 — Amount transferred to receivables from contract assets (68 ) — Increases due to invoicing prior to satisfaction of performance obligations — 2,890 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (3,609 ) January 31, 2018 $ 107 $ 4,886 Contract asset additions 615 — Amount transferred to receivables from contract assets (86 ) — Increases due to invoicing prior to satisfaction of performance obligations — 5,900 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (4,298 ) January 31, 2019 $ 636 $ 6,488
Deferred contract acquisition costs	The following table represents a rollforward of deferred contract acquisition costs: January 31, October 31, 2019 2019 Beginning balance $ 2,334 $ 3,194 Additions to deferred contract acquisition costs 2,500 1,414 Amortization of deferred contract acquisition costs (1,640 ) (1,465 ) Ending balance 3,194 3,143 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,673 1,631 Deferred contract acquisition costs, non current 1,521 1,512 Total deferred contract acquisition costs $ 3,194 $ 3,143	The following table represents a rollforward of deferred contract acquisition costs: January 31, 2018 2019 Beginning balance $ 1,950 $ 2,334 Additions to deferred contract acquisition costs 1,773 2,500 Amortization of deferred contract acquisition costs (1,389 ) (1,640 ) Ending balance $ 2,334 $ 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,640 1,673 Deferred contract acquisition costs, non current 694 1,521 Total deferred contract acquisition costs $ 2,334 $ 3,194

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued liabilities	Accrued expenses as of January 31, 2019 and October 31, 2019 are as follows: January 31, October 31, 2019 2019 Payment processing fees liability $ 2,267 $ 2,428 Commission and bonus 320 2,653 Accrued payment related to acquisition of Vital Score 350 350 Vacation 417 543 Other 1,744 2,044 Total $ 5,098 $ 8,018	Accrued expenses at January 31, 2018 and 2019 are as follows: January 31, 2018 2019 Payment processing fees liability $ 1,858 $ 2,267 Commission and bonus 2,365 320 Acquisition — 350 Vacation 402 417 Other 1,763 1,744 Total $ 6,388 $ 5,098
Schedule of property and equipment	Property and equipment as of January 31, 2019 and October 31, 2019 are as follows: Useful life January 31, October 31, 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 22,747 $ 26,470 Computer equipment 3 14,338 17,093 Computer software 3 2,166 2,223 Hardware development 3 1,024 1,024 Furniture and fixtures 7 647 683 Leasehold improvements 2 1,151 1,175 Total property and equipment $ 42,073 $ 48,668 Less accumulated depreciation and amortization (27,862 ) (34,304 ) Property and equipment—net $ 14,211 $ 14,364	Property and equipment at January 31, 2018 and 2019 are as follows: Useful life January 31, 2018 2019 PhreesiaPads and Arrivals Stations 3 $ 19,936 $ 22,747 Computer equipment 3 9,214 14,338 Computer software 3 2,139 2,166 Hardware development 3 709 1,024 Furniture and fixtures 7 612 647 Leasehold improvements 2 893 1,151 Total property and equipment $ 33,503 $ 42,073 Less accumulated depreciation and amortization (20,333 ) (27,862 ) Property and equipment—net $ 13,170 $ 14,211
Schedule of intangible assets	The following presents the details of intangible assets as of January 31, 2019 and October 31, 2019. Useful life (years) January 31, October 31, 2019 2019 Acquired technology gross carrying value 5 $ 490 $ 490 Customer relationship gross carrying value 7 980 980 Total intangible assets $ 1,470 $ 1,470 Less accumulated amortization (33 ) (212 ) Net carrying value $ 1,437 $ 1,258	The following presents the details of intangible assets as of January 31, 2019. There were no intangible assets as of January 31, 2018. January 31, 2019 Gross carrying Accumulated Net Life Remaining Acquired technology $ 490 $ (14 ) $ 476 5 4.8 Customer Relationship 980 (19 ) 961 7 6.8 $ 1,470 $ (33 ) $ 1,437
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of October 31, 2019: 2020 (Remaining three months) $ 60 Years ending January 31, 2021 238 2022 238 2023 238 2024 224 2025—thereafter 260 Total $ 1,258	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2019: Year Ending January 31, 2020 $ 238 2021 238 2022 238 2023 238 2024 224 Thereafter 261 $ 1,437
Schedule of goodwill		The changes in the carrying amount of goodwill were as follows. There was not any goodwill balance in fiscal 2018. Balance at February 1, 2018 $ — Vital Score Acquisition 250 Balance at January 31, 2019 $ 250
Schedule of accounts receivable	Accounts receivable as of January 31, 2019 and October 31, 2019 are as follows: January 31, October 31, 2019 2019 Billed $ 15,990 $ 19,759 Unbilled 636 978 Total accounts receivable, gross $ 16,626 $ 20,737 Less allowance for doubtful accounts (517 ) (729 ) Total accounts receivable $ 16,109 $ 20,008	Accounts Receivable at January 31, 2018 and 2019 are as follows: January 31, 2018 2019 Billed $ 12,744 $ 15,990 Unbilled 107 636 12,851 16,626 Less: Allowance for doubtful accounts (542 ) (517 ) $ 12,309 $ 16,109

Debt (Tables)

Debt (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of January 31, 2019 and October 31, 2019, the Company had the following outstanding loan balances: January 31, 2019 October 31, 2019 Term loan $ 1,042 $ 20,000 Line of credit 7,800 — Loan payable 20,000 — Total debt $ 28,842 $ 20,000 Less current maturities (97 ) — Less deferred financing costs (996 ) (983 ) Plus accrued interest — 121 Plus accrued final payment 169 217 Long term debt, net of current portion $ 27,918 $ 19,355	As of January 31, 2018 and 2019, the Company had the following outstanding loan balances: January 31, 2018 2019 Term loan $ 2,208 $ 1,042 Line of credit — 7,800 Loan payable 20,000 20,000 $ 22,208 $ 28,842 Less current maturities (1,167 ) (97 ) Less deferred financing costs (1,730 ) (996 ) Plus accrued Final payment 142 169 Long term debt, net of current portion $ 19,453 $ 27,918
Schedule of maturities of long-term debt	As of October 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining three months) $ — Year ending January 31, 2021 — 2022 6,111 2023 6,667 2024 6,667 2025—thereafter 555 Total long-term debt payments $ 20,000	As of January 31, 2019, the Company’s long-term debt is payable as follows (based on the terms of the New Loan Agreement): Year Ending January 31, 2020 $ 97 2021 — 2022 6,111 2023 6,667 2024 6,667 Thereafter 9,300 28,842 Less current portion (97 ) $ 28,745

Common stock (Tables)

Common stock (Tables) - Common Stock [Member]	12 Months Ended
	Jan. 31, 2019
Schedule of Common Shares Outstanding	Each share of common stock is entitled to one vote per share, pursuant to certain restrictions. January 31, 2018 2019 Shares Amount Shares Amount Common stock 1,638,331 $ 16 1,994,721 $ 20
Schedule of the Company has reserved the following shares of common stock for future issuance	As of January 31, 2018 and 2019, the Company has reserved the following shares of common stock for future issuance: January 31, 2018 2019 Senior redeemable convertible preferred stock (Senior A) 6,223,202 6,223,202 Senior redeemable convertible preferred stock (Senior B) 4,185,616 4,185,616 Junior convertible preferred stock 14,902,717 14,902,717 Warrants to purchase Senior A redeemable convertible preferred stock 358,979 358,979 Warrants to purchase Junior redeemable convertible preferred stock 258,675 222,819 Warrants to purchase common stock 256,411 256,411 Employee stock options 5,291,791 5,055,505 Total 31,477,391 31,205,249

Preferred stock (Tables)

Preferred stock (Tables)	12 Months Ended
	Jan. 31, 2019
Preferred Stock [Abstract]
Schedule of preferred stock outstanding shares and amount	The number of outstanding shares and amount of preferred stock are as follows: January 31, 2018 2019 Shares Amount Shares Amount Senior redeemable convertible preferred stock (Senior A) 13,674,365 $ 57,022 13,674,365 $ 79,311 Senior redeemable convertible preferred stock (Senior B) 9,197,142 43,962 9,197,142 51,872 Senior Preferred 22,871,507 100,984 22,871,507 131,183 Junior convertible preferred stock 32,746,041 32,746 32,746,041 32,746 Redeemable preferred stock 42,560,530 42,561 42,560,530 42,561 Total 98,178,078 $ 176,291 98,178,078 $ 206,490

Equity-based compensation (Tabl

Equity-based compensation (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of weighted average assumptions	The weighted average assumptions are provided below. For the nine months ended October 31, October 31, Risk-free interest rate 2.83% 2.18% Expected dividends None None Expected term (in years) 6.25 6.25 Volatility 45.00% 45.15% Weighted average fair market value of grants $ 3.72 $ 4.99	The risk-free rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. January 31, 2018 2019 Risk-free interest rate 2.59% 2.81% Expected dividends None None Expected term (in years) 6.25 6.25 Volatility 41.00% 40.00% Weighted average fair value of grants $ 2.07 $ 3.47
Schedule of stock option activity	Stock option activity for the nine months ended October 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding—January 31, 2019 5,055,505 $ 2.45 Granted in the nine months ended October 31, 2019 1,230,382 $ 8.78 Exercised (111,515 ) $ 3.98 Forfeited and expired (53,627 ) $ 3.38 Outstanding and expected to vest—October 31, 2019 6,120,745 $ 3.67 6.35 $ 140,339 Exercisable—October 31, 2019 4,197,481 $ 2.09 4.84 $ 103,178 Amount vested in the nine months ended October 31, 2019 621,206 $ 4.03	Stock option activity for fiscal 2018 and fiscal 2019 are as follows: Number of Weighted- Weighted- Aggregate Outstanding—February 1, 2017 4,295,364 $ 1.53 Granted during the year 1,295,132 $ 4.71 Exercised (143,600 ) $ 1.03 Forfeited and expired (155,105 ) $ 2.36 Outstanding—January 31, 2018 5,291,791 $ 2.30 Exercisable—January 31, 2018 3,260,333 $ 1.36 Amount vested in fiscal 2018 684,322 $ 1.91 Outstanding—February 1, 2018 5,291,791 $ 2.30 Granted during the year 262,566 $ 4.71 Exercised (316,063 ) $ 1.15 Forfeited (182,789 ) $ 3.72 Outstanding and expected to vest—January 31, 2019 5,055,505 $ 2.45 6.40 $ 28,217 Exercisable—January 31, 2019 3,658,339 $ 1.76 5.48 $ 23,072 Amount vested in fiscal 2019 736,028 $ 3.27
Schedule of Restricted Stock Unit Activity	Restricted stock unit activity for the nine months ended October 31, 2019 are as follows: Restricted stock units Balance—January 31, 2019 20,164 Granted 526,382 Forfeited (22,185 ) Balance—October 31, 2019 524,361

Stock warrant liabilities (Tabl

Stock warrant liabilities (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrants to purchase common and preferred stock outstanding	As of January 31, 2019 and October 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase January 31, October 31, Exercise price Expiration Senior A Preferred 116,232 — $ 2.19 October 1, 2021 Senior A Preferred 672,560 — $ 3.00 November 1, 2026 Junior Preferred 489,605 — $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) 1,636,641 — Common stock 166,952 — $ 2.02 October 21, 2025 Common stock 89,459 — $ 3.49 November 1, 2026 Common stock — 75,137 $ 8.02 February 28, 2029 Common stock (converted from preferred stock warrants) — 153,041 $ 6.59 November 1, 2026 Total common stock (equity-classified) 256,411 228,178	As of January 31, 2018 and 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase 2018 2019 Exercise Expiration Senior A Preferred 116,232 116,232 $ 2.19 October 1, 2021 Senior A Preferred 672,560 672,560 $ 3.00 November 1, 2026 Junior Preferred 489,605 489,605 $ 0.01 September 5, 2020 Junior Preferred 32,590 — $ 1.00 February 2, 2018 Junior Preferred 46,197 — $ 1.00 April 15, 2018 Redeemable Preferred 358,244 358,244 $ 0.01 September 5, 2020 Redeemable Preferred 23,846 — $ 0.73 February 2, 2018 Redeemable Preferred 33,802 — $ 0.73 April 15, 2018 Total preferred stock (liability-classified) 1,773,076 1,636,641 Common stock 166,952 166,952 $ 2.02 October 21, 2025 Common stock 89,459 89,459 $ 3.49 November 1, 2026 Total common stock (equity-classified) 256,411 256,411
Schedule of summarizes the activity for the company's warrants	The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance—January 31, 2019 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (760,305 ) (1,636,641 ) Balance—October 31, 2019 228,178 —	The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance at February 1, 2017 256,411 1,813,076 Exercised — (40,000 ) Balance—January 31, 2018 256,411 1,773,076 Forfeited — (136,435 ) Balance—January 31, 2019 256,411 1,636,641
Schedule of reconciliation of the warrant liability measured at fair value	The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants nine months ended October 31, 2019 3,307 Conversion of convertible preferred stock warrants (8,805 ) Balance at October 31, 2019 $ —	The following table is a reconciliation of the warrant liability measured at fair value: Warrant liability Balance at February 1, 2017 $ 2,870 Exercised (28 ) Change in fair value of stock warrants during year 598 Balance at January 31, 2018 $ 3,440 Change in fair value of stock warrants during year 2,058 Balance at January 31, 2019 $ 5,498

Fair value measurements (Tables

Fair value measurements (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of measure the fair market value of the warrant liability	The Black-Scholes Method and the following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior preferred Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9% 1.9% Expected volatility 45.9% 45.9% Dividend yield 0.0% 0.0%	The Black-Scholes method and the following weighted-average inputs and assumptions was utilized to determine the fair value of the warrants as of January 31, 2018 and 2019: January 31, 2018 Series A Preferred Junior Redeemable Estimated fair value of preferred stock $ 4.17 $ 2.38 $ 0.79 Exercise price $ 2.88 $ 0.15 $ 0.11 Remaining term (in years) 8.01 2.25 2.25 Risk-free interest rate 2.4% 1.8% 1.8% Expected volatility 37.8% 38.8% 38.8% Dividend yield 0.0% 0.0% 0.0% January 31, 2019 Series A Preferred Junior Redeemable Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6% 2.5% 2.5% Expected volatility 45.1% 45.1% 45.1% Dividend yield 0.0% 0.0% 0.0%
Schedule of weighted-average inputs and assumptions	The Black-Scholes method and the following weighted-average inputs and assumptions were utilized to determine the fair value of the warrants as of January 31, 2019, pre-stock January 31, 2019 Series A Junior Redeemable preferred Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6% 2.5% 2.5% Expected volatility 45.1% 45.1% 45.1% Dividend yield 0.0% 0.0% 0.0%

Commitments and contingencies (

Commitments and contingencies (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate minimum net rental payments	As of October 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining three months) $ 443 Year ending January 31, 2021 1,824 2022 819 2023 464 Total operating lease payments $ 3,550	As of January 31, 2019, the aggregate minimum net rental payments for non-cancelable January 31, 2020 $ 1,736 2021 1,751 2022 745 2023 225 $ 4,457
Schedule of minimum lease payments	During the nine months ended October 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining three months) $ 611 Year ending January 31, 2021 2,404 2022 1,621 2023 200 Total capital lease payments $ 4,836 Less amounts representing interest (452) Total capital lease payments, net of interest 4,384 Less current portion (2,413) Total capital lease payments, net of interest and current portion $ 1,971	During fiscal year ended January 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 January 31, 2020 $ 2,282 2021 1,767 2022 984 $ 5,033 Less: Amounts representing interest (763 ) $ 4,270 Less: Current portion (1,869 ) $ 2,401

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jan. 31, 2019
Income Tax Disclosure [Abstract]
Company's Deferred Tax Assets and Deferred Tax Liabilities	The tax effects of temporary differences and carryforwards that give rise to deferred tax assets and deferred tax liabilities at January 31, 2018 and 2019, are as follows: January 31, Deferred tax assets 2018 2019 Net operating losses $ 27,464 $ 29,068 Stock options 274 516 Other 248 276 Vacation 104 111 Reserve for bad debts 55 73 Disallowed interest expense — 415 Depreciation — 278 Total Deferred tax assets $ 28,145 $ 30,737 Deferred tax liability—depreciation (437 ) — Deferred contract acquisition costs (607 ) (849 ) Total net deferred tax asset $ 27,101 $ 29,888 Less valuation allowance (27,101 ) (29,888 ) Net deferred tax asset $ — $ —

Net loss per share and unaudi_2

Net loss per share and unaudited pro forma net loss per share attributable to common stockholders (Tables)	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Nine months ended October 31, 2018 2019 Numerator: Net loss $ (9,983 ) $ (16,625 ) Preferred stock dividend paid — (14,955 ) Accretion of redeemable convertible preferred stock to redemption value (20,962 ) (56,175 ) Net loss attributable to common stockholders $ (30,945 ) $ (87,755 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,176,833 15,007,247 Net loss attributable to common stockholders $ (26.30 ) $ (5.85 )	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended January 31, 2018 2019 Numerator: Net loss $ (18,192 ) $ (15,062 ) Accretion of Convertible Preferred to redemption value (19,981 ) (30,199 ) Net loss attributable to common stockholders $ (38,173 ) $ (45,261 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,538,600 1,844,929 Net loss attributable to common stockholders, basic and diluted $ (24.81 ) $ (24.53 )
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: October 31, October 31, Redeemable convertible preferred stock (as-converted 25,311,535 - Stock options to purchase common stock and restricted stock units 5,094,108 6,645,106 Warrants to purchase convertible preferred stock 581,798 - Warrants to purchase common stock 256,411 228,178 31,243,852 6,873,284	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended January 31, 2018 2019 Convertible Preferred (as-converted 25,311,535 25,311,535 Stock options to purchase common stock 5,291,791 5,055,505 Warrants to purchase Convertible Preferred 617,654 581,798 Warrants to purchase common stock 256,411 256,411 Total 31,477,391 31,205,249
Pro Forma [Member]
Schedule of earnings per share, basic and diluted		Unaudited pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended Numerator: Net loss attributable to common stockholders $ (45,261 ) Pro forma adjustments: Accretion of preferred stock 30,199 Change in fair value of warrant 177 Pro Forma net loss attributable to common stockholders, basic and diluted $ (14,885 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 1,844,929 Pro Forma adjustments: Assumed conversion of preferred stock 25,311,535 Cashless exercise of warrants 36,959 Share assumed issued to pay dividends 1,129,539 Pro Forma weighted-average common shares outstanding, basic and diluted 28,322,962 Pro Forma net loss per share attributable to common stockholders, basic and diluted $ (0.53 )

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Jan. 31, 2019
Business Combinations [Abstract]
Summary of Purchase Price Consideration Based on Estimated Acquisition Fair Value	The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration $ 1,540 Common stock issued (20,164 shares at $8.03 per share) 162 Total fair value of acquisition consideration $ 1,702
Schedule of Final Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Property and equipment $ 5 Acquired technology 490 Customer relationships 980 Goodwill 250 Total assets acquired $ 1,725 Accounts payable (23 ) Total purchase price $ 1,702

Background and liquidity - Addi

Background and liquidity - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 03, 2019	Oct. 31, 2019	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)
Background And Liquidity [Line Items]
Year formed				2005		2005
Stockholder equity reverse stock splits		0.4551-for-1
Reverse stock splits shares combined		2.1973
Proceeds from issuance initial public offering				$ 130,781	$ 0
Deferred offering costs				5,944	0	$ 195	$ 0
Payments of preferred stock dividends				$ 14,955	$ 0
Minimum [Member]
Background And Liquidity [Line Items]
Period through to sufficiently fund operations						2020-04
Number of months the company have sufficient to fund its operations			12 months
IPO [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering, shares | shares	7,812,500
Share price | $ / shares	$ 18
Proceeds from issuance initial public offering	$ 130,781
Underwriting discounts and commission	9,844
Deferred offering costs	$ 6,084
Conversion and exercise of preferred stock warrants | shares	588,763
Payments of preferred stock dividends	$ 14,955
IPO [Member] | Stockholders [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering, shares | shares	2,868,923

Summary of significant accoun_2

Summary of significant accounting policies - Additional Information (Detail) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Jan. 31, 2019USD ($)$ / shares	Jan. 31, 2018USD ($)	Jul. 31, 2019USD ($)	Jul. 22, 2019USD ($)
Schedule Of Components Of Other Revenues [Line Items]
Revenue from Contract with Customer	$ 91,968	$ 73,406	$ 99,889	$ 79,834
Capitalized contract cost, amortization	1,465	1,179	1,640	$ 1,389
Capitalized contract cost, amortization period				3 years
Allowance for doubtful accounts			517	$ 542
Capitalized computer software net	8,501		$ 7,816	6,715
Number of operating segment			1
Dividend yield | $ / shares			$ 0
Deferred offering costs	56				$ 6,084	$ 6,084
Junior Preferred and Redeemable Preferred [Member]
Schedule Of Components Of Other Revenues [Line Items]
Redeemable preferred stock, redemption price per share | $ / shares			$ 1
Phreesia Platform Software [Member]
Schedule Of Components Of Other Revenues [Line Items]
Capitalized cost of computer software	4,329	3,744	$ 5,109	5,375
Capitalized computed software amortization	3,645	2,912	4,009	2,808
Capitalized computer software net	8,501		$ 7,816	6,715
Computer Software [Member]
Schedule Of Components Of Other Revenues [Line Items]
Intangible asset, estimated useful life			3 years
Minimum [Member]
Schedule Of Components Of Other Revenues [Line Items]
Property and equipment Useful Life			3 years
Maximum [Member]
Schedule Of Components Of Other Revenues [Line Items]
Property and equipment Useful Life			6 years
Other Assets [Member]
Schedule Of Components Of Other Revenues [Line Items]
Deferred offering costs			$ 540
Selling and Marketing Expense [Member]
Schedule Of Components Of Other Revenues [Line Items]
Capitalized contract cost, amortization	$ 1,465	$ 1,179	1,640	1,389
Advertising expense			$ 134	17
Subscription and Related Services [Member]
Schedule Of Components Of Other Revenues [Line Items]
Subscription fees, percentage generated from base package and add-ons			95.00%
Subscription and Related Services [Member] | Onsite Kiosks [Member]
Schedule Of Components Of Other Revenues [Line Items]
Revenue from Contract with Customer			$ 4,749	$ 3,544

Significant accounting policies

Significant accounting policies - Rollforward of contract assets and contract liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Accounting Policies [Abstract]
Beginning balance	$ 636	$ 107	$ 78
Contract asset additions	918	615	96
Amount transferred to receivables from contract assets	(576)	(86)	(68)
Ending balance	978	636	107
Beginning balance	6,488	4,886	5,605
Increases due to invoicing prior to satisfaction of performance obligations	10,006	5,900	2,890
Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period	(11,168)	(4,298)	(3,609)
Ending balance	$ 5,326	$ 6,488	$ 4,886

Significant accounting polici_2

Significant accounting policies - Schedule of Deferred contract acquisition costs (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Accounting Policies [Abstract]
Beginning balance	$ 3,194	$ 2,334	$ 2,334	$ 1,950
Additions to deferred contract acquisition costs	1,414		2,500	1,773
Amortization of deferred contract acquisition costs	(1,465)	(1,179)	(1,640)	(1,389)
Ending balance	3,143		3,194	2,334
Deferred contract acquisition costs, current (to be amortized in next 12 months)					$ 1,631	$ 1,673	$ 1,640
Deferred contract acquisition costs, non current					1,512	1,521	694
Total deferred contract acquisition costs	$ 3,143	$ 2,334	$ 3,194	$ 2,334	$ 3,143	$ 3,194	$ 2,334

Composition of Certain Financ_3

Composition of Certain Financial Statement Captions - Schedule of accrued liabilities (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Accrued Expenses [Abstract]
Payment processing fees liability	$ 2,428	$ 2,267	$ 1,858
Commission and bonus	2,653	320	2,365
Accrued payment related to acquisition of Vital Score	350	350
Vacation	543	417	402
Other	2,044	1,744	1,763
Total	$ 8,018	$ 5,098	$ 6,388

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 48,668	$ 42,073	$ 33,503
Less accumulated depreciation and amortization	(34,304)	(27,862)	(20,333)
Property and equipment-net	$ 14,364	$ 14,211	13,170
PhreesiaPads and Arrivals Stations [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	3 years	3 years
Property and equipment Gross	$ 26,470	$ 22,747	19,936
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	3 years	3 years
Property and equipment Gross	$ 17,093	$ 14,338	9,214
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	3 years	3 years
Property and equipment Gross	$ 2,223	$ 2,166	2,139
Hardware Development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	3 years	3 years
Property and equipment Gross	$ 1,024	$ 1,024	709
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	7 years	7 years
Property and equipment Gross	$ 683	$ 647	612
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Useful Life	2 years	2 years
Property and equipment Gross	$ 1,175	$ 1,151	$ 893

Composition of certain financ_5

Composition of certain financial statement captions - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Jul. 31, 2019	Jul. 22, 2019
Composition Of Certain Financial Statement [Line Items]
Depreciation	$ 6,444	$ 5,515	$ 7,552	$ 6,832
Capital Leased Assets, Gross	11,973		10,235	5,810
Accumulated amortization of capital lease assets	7,127		5,639	3,275
Amortization expense	178	0	33
Capitalized computer software net	8,501		7,816	6,715
Deferred offering costs	56				$ 6,084	$ 6,084
Other Assets [Member]
Composition Of Certain Financial Statement [Line Items]
Deferred offering costs			540
Phreesia Platform Software [Member]
Composition Of Certain Financial Statement [Line Items]
Capitalized cost of computer software	4,329	3,744	5,109	5,375
Capitalized computed software amortization	3,645	$ 2,912	4,009	2,808
Capitalized computer software net	$ 8,501		$ 7,816	$ 6,715
Acquired Technology [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of acquired intangible assets	4 years 1 month 6 days		4 years 9 months 18 days
Customer Relationships [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of acquired intangible assets	6 years 1 month 6 days		6 years 9 months 18 days
Depreciation [Member]
Composition Of Certain Financial Statement [Line Items]
Capital leases depreciation	$ 1,758

Composition of certain financ_6

Composition of certain financial statement captions - Schedule Of Finite Lived Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 1,470	$ 1,470
Accumulated amortization	(212)	(33)	$ 0
Net	1,258	1,437	$ 0
Acquired technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 490	490
Accumulated amortization		(14)
Net		$ 476
Finite-lived intangible asset, useful life	5 years	5 years
Remaining useful life (in years)		4 years 9 months 18 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 980	$ 980
Accumulated amortization		(19)
Net		$ 961
Finite-lived intangible asset, useful life	7 years	7 years
Remaining useful life (in years)		6 years 9 months 18 days

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 60	$ 238
2021	238	238
2022	238	238
2023	238	238
2024	224	224
2025-thereafter	260	261
Net carrying value	$ 1,258	$ 1,437	$ 0

Composition of certain financ_8

Composition of certain financial statement captions - schedule of goodwill (Detail) $ in Thousands	12 Months Ended
	Jan. 31, 2019USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning balance	$ 0
Ending balance	250
Vital Score Acquisition [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Vital Score Acquisition	$ 250

Composition of certain financ_9

Composition of certain financial statement captions - Schedule Of Accounts Notes Loans And Financing Receivable (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Accounts Receivable Additional Disclosures [Abstract]
Billed	$ 19,759	$ 15,990	$ 12,744
Unbilled	978	636	107
Total accounts receivable, gross	20,737	16,626	12,851
Less allowance for doubtful accounts	(729)	(517)	(542)
Total accounts receivable	$ 20,008	$ 16,109	$ 12,309

Debt - Schedule Of Outstanding

Debt - Schedule Of Outstanding loan balances (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jan. 31, 2018
Shares Issued And Outstanding [Line Items]
Line of credit	$ 20,000	$ 28,842		$ 22,208
Less current maturities	0	(97)		(1,167)
Less deferred financing costs	(983)	(996)		(1,730)
Plus accrued interest	121
Plus accrued Final payment	217	169		142
Long term debt, net of current portion	19,355	27,918		19,453
Term Loan [Member]
Shares Issued And Outstanding [Line Items]
Line of credit	$ 20,000	1,042		2,208
Plus accrued Final payment		28		51
Line of Credit [Member]
Shares Issued And Outstanding [Line Items]
Line of credit		7,800
Loans Payable [Member]
Shares Issued And Outstanding [Line Items]
Line of credit		$ 20,000	$ 20,000	$ 20,000

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2019	Feb. 28, 2019	Jan. 31, 2019	Nov. 07, 2016	Feb. 28, 2019	May 31, 2017	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Debt [Line Items]
Long term debt gross			$ 28,842				$ 20,000		$ 28,842	$ 22,208
Prepayment fee							300
Final fee charged to interest			169				$ 217		169	142
Number of securities called by warrants							428,757
Repayments of revolving credit	$ 17,676						$ 17,676	$ 3,500	7,000	20,400
Write-off of deferred financing costs							773
Extinguishment and modification fee							(1,073)	0
Debt issuance costs							112	0	136	224
Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Borrowing capacity		$ 15,000			$ 15,000
Prepayment fee percentage		3.00%
Prepayment fee percentage		2.00%
Prepayment fee percentage		1.00%
Number of securities called by warrants		150,274			150,274
Exercise price		$ 8.02			$ 8.02
Warrants expiration period		2029-02
Warrants fair value disclosure		$ 833			$ 833
Term Loan [Member]
Debt [Line Items]
Borrowing capacity			3,500					3,500	3,500
Long term debt gross			$ 1,042				$ 20,000		$ 1,042	$ 2,208
Expiration period							36 months		36 months
Description of variable rate basis			Prime Rate was 5.50%						Prime Rate was 4.50% and 5.50%	Prime Rate was 4.50% and 5.50%
Interest rate description							Prime Rate as quoted by the Wall Street Journal print edition less three-quarters of one percent (0.75%)		Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%)
Prepayment fee			$ 175				$ 175		$ 175
Debt instrument fee percentage							5		5
Final fee charged to interest			$ 28						$ 28	$ 51
Interest expense							$ 16	73	121	245
Amortization of financing costs							5	$ 18	$ 23	$ 98
Effective interest rate percentage			7.40%					5.10%	7.40%	8.80%
Final fee charged to interest							6	$ 21
Term Loan [Member] | Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Long term debt gross			$ 1,042						$ 1,042
Description of variable rate basis		Prime rate plus 1.50%
Final fee charged to interest							217
Interest expense							1,046
Amortization of financing costs							$ 103
Effective interest rate percentage							3.90%
Debt, borrowing capacity		$ 20,000			20,000
Loan agreement, term							Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021		Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021
Description of variable rate basis		Prime plus 0.75%
Debt instrument fee percentage		2.75%
Loans Payable [Member]
Debt [Line Items]
Borrowing capacity			10,000	$ 10,000				10,000	$ 10,000
Long term debt gross			$ 20,000					20,000	20,000	$ 20,000
Expiration period				5 years
Interest expense							$ 168	1,663	2,729	2,401
Amortization of financing costs							$ 0	$ 89	$ 499	$ 507
Effective interest rate percentage			13.60%					12.50%	13.60%	14.20%
Debt, additional available amount				$ 10,000
Proceeds from lines of credit				$ 10,000		$ 10,000
Loan agreement, term							Principal due in 30 equal installments beginning in June 2019.		Principal was due in 30 equal installments beginning in June 2019.
Stated interest percentage				11.00%
Loans Payable [Member] | Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Long term debt gross			$ 20,000						$ 20,000
Revolving Credit Facility [Member]
Debt [Line Items]
Description of variable rate basis							Prime rate plus 1.00%		Prime rate plus 1.00%
Interest expense							$ 166	$ 115	$ 364	$ 786
Amortization of financing costs							13	53	248
Debt, borrowing capacity			20,000				$ 20,000		$ 20,000
Maturity date							Nov. 30, 2019		Nov. 30, 2019
Weighted-average borrowings outstanding							$ 979	$ 971	$ 971	$ 8,658
Repayments of revolving credit					97
Revolving Credit Facility [Member] | Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Borrowing capacity			16,300				$ 25,000		16,300
Long term debt gross			$ 7,800						$ 7,800
Expiration period							5 years
Interest rate description							Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank's prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%.		Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75% , or 4.75%.
Interest expense							$ 342
Amortization of financing costs							84
Debt, borrowing capacity		$ 25,000			25,000		$ 25,000
Maturity date							Feb. 28, 2024
Debt instrument fee percentage									0.15%
Borrowing capacity decription							Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate.		Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate.
Annual fee per year in years four and five							$ 75		$ 75
Annual fee per year during the first three years							$ 100		$ 100
Termination fee percentage									1.50%
Term Loan B Advance [Member] | Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Borrowing capacity		10,000			10,000
Term Loan C Advance [Member] | Amended And Restated Loan And Security Agreement [Member]
Debt [Line Items]
Borrowing capacity		$ 15,000			$ 15,000

Debt - Schedule of long-term de

Debt - Schedule of long-term debt maturities (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Debt Disclosure [Abstract]
2020		$ 97
2020 (Remaining three months) Year ending January 31,	$ 0
2021	0	0
2022	6,111	6,111
2023	6,667	6,667
2024	6,667	6,667
2025-thereafter	555	9,300
Line of credit	20,000	28,842	$ 22,208
Less current portion	0	(97)	$ (1,167)
Total long-term debt payments	$ 20,000	$ 28,745

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2019	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Class of Stock [Line Items]
Common stock authorized		500,000,000		80,000,000	80,000,000
Common stock par value		$ 0.01		$ 0.01	$ 0.01
Proceeds from proceeds from issuance intial public offering		$ 130,781	$ 0
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock converted	25,311,515
IPO [Member]
Class of Stock [Line Items]
Common stock authorized	500,000,000
Common stock par value	$ 0.01
Stock issued during period initial public offering	7,812,500
Share price	$ 18
Proceeds from proceeds from issuance intial public offering	$ 130,781
Convertible preferred stock converted	588,763
Cashless exercise of common stock warrants		53,023

Common Stock - Schedule of comm

Common Stock - Schedule of common stock is entitled to one vote per share (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017
Class of Stock [Line Items]
Amount	$ 102,493	$ 102,852	$ (224,063)	$ (210,974)	$ (197,353)	$ (184,558)	$ (172,999)	$ (167,683)	$ (130,462)
Common Stock [Member]
Class of Stock [Line Items]
Shares	35,872,057	35,759,355	2,024,519	1,994,721	1,944,445	1,785,948	1,769,891	1,638,331	1,494,731
Amount	$ 359	$ 357	$ 20	$ 20	$ 19	$ 17	$ 17	$ 16	$ 15

Common Stock - Schedule of Co_2

Common Stock - Schedule of Common Stock Capital Shares Reserved For Future Issuance (Detail) - shares	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Class of Stock [Line Items]
Common stock shares reserved for future issuance		31,205,249	31,477,391
Employee Stock [Member]
Class of Stock [Line Items]
Common stock shares reserved for future issuance		5,055,505	5,291,791
Common Stock [Member]
Class of Stock [Line Items]
Warrants to purchase	228,178	256,411	256,411	256,411
Senior A Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common stock shares reserved for future issuance		6,223,202	6,223,202
Warrants to purchase		358,979	358,979
Senior B Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common stock shares reserved for future issuance		4,185,616	4,185,616
Junior Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common stock shares reserved for future issuance		14,902,717	14,902,717
Warrants to purchase		222,819	258,675

Preferred Stock - Schedule of p

Preferred Stock - Schedule of preferred stock outstanding shares and amount (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017
Preferred Stock [Line Items]
Shares				98,178,078				98,178,078
Amount	$ 0			$ 206,490				$ 176,291
Senior A Redeemable Preferred Stock [Member]
Preferred Stock [Line Items]
Shares	0			13,674,365				13,674,365
Amount	$ 0			$ 79,311				$ 57,022
Series B Redeemable Convertible Preferred Stock [Member]
Preferred Stock [Line Items]
Shares	0	0	9,197,142	9,197,142	9,197,142	9,197,142	9,197,142	9,197,142
Amount	$ 0		$ 54,539	$ 51,872	$ 49,596	$ 47,321	$ 45,046	$ 43,962
Senior Preferred Stock [Member]
Preferred Stock [Line Items]
Shares				22,871,507				22,871,507
Amount				$ 131,183				$ 100,984
Junior Convertible Preferred Stock [Member]
Preferred Stock [Line Items]
Shares	0	0	32,746,041	32,746,041	32,746,041	32,746,041	32,746,041	32,746,041	32,718,098
Amount	$ 0		$ 32,746	$ 32,746	$ 32,746	$ 32,746	$ 32,746	$ 32,746	$ 32,718
Redeemable Preferred Stock [Member]
Preferred Stock [Line Items]
Shares	0	0	42,560,530	42,560,530	42,560,782	42,560,782	42,560,530	42,560,530	42,560,530
Amount	$ 0		$ 42,561	$ 42,561	$ 42,561	$ 42,561	$ 42,561	$ 42,561	$ 42,561

Preferred stock - Additional in

Preferred stock - Additional information (Detail)	Jul. 22, 2019USD ($)$ / sharesshares	Nov. 29, 2017USD ($)shares	Oct. 27, 2017USD ($)$ / sharesshares	Oct. 14, 2014USD ($)$ / sharesshares	Jul. 31, 2019shares	Oct. 31, 2019USD ($)shares	Oct. 31, 2018USD ($)shares	Jan. 31, 2019USD ($)$ / sharesshares	Jan. 31, 2018USD ($)shares	Nov. 14, 2019$ / shares	Apr. 30, 2019shares	Jul. 31, 2018shares	Apr. 30, 2018shares	Jan. 31, 2017shares
Proceeds from issuance of preferred shares | $								$ 0	$ 32,459,000
Preferred stock issued in exchange								25,311,535
Aggregate of common stock						35,759,355		1,994,721	1,638,331
Temporary equity, shares outstanding								98,178,078	98,178,078
Preferred stock authorized	20,000,000
Preferred stock par value | $ / shares	$ 0.01
Dividend paid | $						$ 14,955,000	$ 0
IPO [Member]
Issue price per share | $ / shares	$ 18
Aggregate of common stock	25,311,515
Dividend paid | $	$ 14,955,000
Senior A Redeemable Preferred Stock [Member]
Temporary equity, shares issued				13,674,365		0		13,674,365	13,674,365
Temporary equity, price per share | $ / shares				$ 2.1939
Proceeds from issuance of preferred shares | $				$ 30,000,000
Issuance cost incurred | $				$ 1,803,000
Temporary equity, shares outstanding						0		13,674,365	13,674,365
Junior Preferred Stock [Member]
Preferred stock issued in exchange				33,344,348
Conversion of Stock, Conversion Price | $ / shares								$ 1.66
Conversion Of Stock, Conversion Ratio								2.1973	2.1973
Redeemable Preferred Stock [Member]
Temporary equity, shares issued						0		42,560,530	42,560,530
Preferred stock issued in exchange				43,214,680
Temporary equity cancelled	42,560,530				(42,560,530)
Temporary equity, shares outstanding					0	0	42,560,782	42,560,530	42,560,530		42,560,530	42,560,782	42,560,530	42,560,530
Series B Redeemable Convertible Preferred Stock [Member]
Temporary equity, shares issued		4,598,571	4,598,571			0		9,197,142	9,197,142
Temporary equity, price per share | $ / shares			$ 3.6968
Proceeds from issuance of preferred shares | $		$ 17,000,000	$ 17,000,000
Issuance cost incurred | $		$ 1,541
Temporary equity cancelled					(9,197,142)
Temporary equity, shares outstanding					0	0	9,197,142	9,197,142	9,197,142		9,197,142	9,197,142	9,197,142
Junior Preferred Stock And Redeemable Preferred Stock [Member]
Issue price per share | $ / shares										$ 1

Dividend - Additional Informati

Dividend - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Dividend And Capital Restrictions [Line Items]
Accuring Dividend Payable Adjustments descripition	The Accruing Dividends payable may be adjusted as follows: (a) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be greater than or equal to 4.5 times the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then no Accruing Dividends would be paid with respect to such share of Senior Preferred; (b) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be less than or equal to 3.5 times the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then 100% of the Accruing Dividends would be paid with respect to such share of Senior Preferred; and (c) if the Participating Amount for the applicable Senior Preferred (calculated on a per share basis) would be greater than 3.5 times and less than 4.5 times (such applicable multiple, the “Special Multiple”) the Senior A Preferred Original Issue Price or the Senior B Preferred Original Issue Price, as applicable, then the amount of the aggregate Accruing Dividends paid with respect to such share of Senior Preferred would equal the product of (a) the Applicable Difference and (b) an amount equal to 100% of the Accruing Dividends (prior to giving effect to any adjustment). The “Applicable Difference” means an amount equal to the difference between 4.5 times and the Special Multiple.
Cumulative undeclared dividends		$ 14,837	$ 8,997
Senior preferred redeemed description		Shares of Senior Preferred shall be redeemed by the Company out of funds lawfully available therefore at a price per share equal to the greater of (i) the fair market value of the Senior Preferred as of the redemption date and (ii) the Senior Preferred Original Issue Price, together with any other dividends declared but unpaid thereon, and any Accruing Dividends accrued by unpaid thereon (the “Senior Preferred Redemption Price”), in three annual installments commencing 60 days after receipt by the Company at any time on or after October 27, 2021, from the holders of at least a majority of the then outstanding shares of Senior Preferred, of written notice requesting redemption of all (but not less than all) shares of Senior Preferred.
Senior A Redeemable Convertible Preferred Stock [Member]
Dividend And Capital Restrictions [Line Items]
Dividend Rate		8.00%
Senior B Redeemable Convertible Preferred Stock [Member]
Dividend And Capital Restrictions [Line Items]
Dividend Rate		8.00%

Equity-based compensation - Add

Equity-based compensation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 20, 2019	Mar. 25, 2019	Oct. 14, 2014	Aug. 31, 2019	Jun. 30, 2019	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance						31,477,391			31,205,249	31,477,391
Intrinsic value							$ 1,728	$ 1,658	$ 1,355	$ 528
Weighted average Term							2 years 11 months 23 days			1 year 11 months 23 days
Option plan expense							$ 2,051	$ 950	1,447,199	$ 805
Unrecognized compensation cost to stock option						$ 3,195	6,975			$ 3,195
Incremental expense associated with the modification of stock options							$ 173
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award							For such executive officers that elected to receive restricted stock units, such award was granted immediately after such election with a value equal to the portion of the target bonus opportunity that the executive officer elected not to receive in cash, and such award vests based on the achievement of the Company’s pre-defined performance targets. Further, such executive officer may earn up to 200% of the target number of restricted stock units based on actual performance, provided that certain stipulations are met.
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognised compensation costs							$ 3,779		155
Restricted stock expense							$ 1,781		$ 7
Expiration date		2026-03
RSU's granted		390,794
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		10.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		20.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		30.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		40.00%
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted				72,126
Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted				4,873
Director [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted	58,589
2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued							151,548		151,548
Expiration date			2017-08
Number of shares available for issuance			4,424,986
Common stock reserve for future issuance									42,213
2018 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized						3,048,490
2019 Stock Option And Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option					25.00%	25.00%
Common stock reserve for future issuance					2,139,683		2,129,560
Percentage increase in number of shares reserved					5.00%
2019 Stock Option And Incentive Plan [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term					6 months
2019 Stock Option And Incentive Plan [Member] | Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term					4 years
2019 Employee Stock Purchse Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance					855,873		855,873

Equity-based compensation - Wei

Equity-based compensation - Weighted Average Assumptions (Detail) - Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.18%	2.83%	2.81%	2.59%
Expected dividends	$ 0	$ 0	$ 0	$ 0
Expected term (in years)	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months
Volatility	45.15%	45.00%	40.00%	41.00%
Weighted average fair market value of grants	$ 4.99	$ 3.72	$ 3.47	$ 2.07

Equity-based compensation - Sto

Equity-based compensation - Stock Option Activity (Detail) - Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	5,055,505	5,291,791	4,295,364
Granted	1,230,382	262,566	1,295,132
Exercised	(111,515)	(316,063)	(143,600)
Forfeited	(53,627)	(182,789)	(155,105)
Number of options outstanding ending balance	6,120,745	5,055,505	5,291,791
Exercisable	4,197,481	3,658,339	3,260,333
Amount vested at the beginning of the period	621,206	736,028	684,322
Weighted- average exercise price outstanding, beginning balance	$ 2.45	$ 2.30	$ 1.53
Granted	8.78	4.71	4.71
Exercised	3.98	1.15	1.03
Forfeited	3.38	3.72	2.36
Weighted- average exercise price outstanding, ending balance	3.67	2.45	2.30
Number of options
Exercisable	2.09	1.76	1.36
Amount vested at the end of the period	$ 4.03	$ 3.27	$ 1.91
Outstanding and expected to vest-October 31, 2019	6 years 4 months 6 days	6 years 4 months 24 days
Weighted- average exercise price outstanding
Exercisable-October 31, 2019	4 years 10 months 2 days	5 years 5 months 23 days
Aggregate intrinsic value outstanding and expected to vest	$ 140,339	$ 28,217
Aggregate intrinsic value exercisable	$ 103,178	$ 23,072

Stock warrants - warrants to pu

Stock warrants - warrants to purchase common and preferred stock (Detail) - $ / shares	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Senior A Preferred | Exercise price 2.19, Expiration October 1, 2021
Class of Warrant or Right [Line Items]
Number of warrants	0	116,232	116,232
Exercise price	$ 2.19	$ 2.19
Common stock	Oct. 1, 2021	Oct. 1, 2021
Senior A Preferred | Exercise price 3.00, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	672,560	672,560
Exercise price	$ 3	$ 3
Common stock	Nov. 1, 2026	Nov. 1, 2026
Junior Preferred Stock [Member] | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants	0	489,605	489,605
Exercise price	$ 0.01	$ 0.01
Common stock	Feb. 5, 2020	Sep. 5, 2020
Junior Preferred Stock [Member] | Exercise Price 1.00 Expiry Date February 2, 2018
Class of Warrant or Right [Line Items]
Number of warrants			32,590
Exercise price		$ 1
Common stock		Feb. 2, 2018
Junior Preferred Stock [Member] | Exercise Price 1.00 Expiry Date April 15, 2018
Class of Warrant or Right [Line Items]
Number of warrants			46,197
Exercise price		$ 1
Common stock		Apr. 15, 2018
Redeemable Preferred Stock [Member] | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants	0	358,244	358,244
Exercise price	$ 0.01	$ 0.01
Common stock	Sep. 5, 2020	Sep. 5, 2020
Redeemable Preferred Stock [Member] | Exercise Price 0.73 Expiry Date 2018 [Member]
Class of Warrant or Right [Line Items]
Number of warrants			23,846
Exercise price		$ 0.73
Common stock		Feb. 2, 2018
Redeemable Preferred Stock [Member] | Exercise Price 0.73 Expiry Date April 15, 2018
Class of Warrant or Right [Line Items]
Number of warrants			33,802
Exercise price		$ 0.73
Common stock		Apr. 15, 2018
Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of warrants	228,178	256,411	256,411
Common Stock [Member] | Exercise price 2.02, Expiration October 21, 2025
Class of Warrant or Right [Line Items]
Number of warrants	0	166,952	166,952
Exercise price	$ 2.02	$ 2.02
Common stock	Oct. 11, 2025	Oct. 21, 2025
Common Stock [Member] | Exercise price 3.49, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	89,459	89,459
Exercise price	$ 3.49	$ 3.49
Common stock	Nov. 1, 2026	Nov. 1, 2026
Common Stock [Member] | Exercise price 8.02, Expiration February 28, 2029
Class of Warrant or Right [Line Items]
Number of warrants	75,137	0
Exercise price	$ 8.02
Common stock	Feb. 28, 2029
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of warrants	0	1,636,641	1,773,076
Common stock (converted from preferred stock) | Exercise price 6.59, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	153,041	0
Exercise price	$ 6.59
Common stock	Nov. 1, 2026

Stock warrants - Activity for t

Stock warrants - Activity for the Company's warrants (Detail) - shares	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Class of Warrant or Right [Line Items]
Exercised			(28,000)
Common Stock [Member]
Class of Warrant or Right [Line Items]
Balance-January 31, 2019	256,411	256,411	256,411
Granted	150,274
Conversion of preferred stock warrants to common stock warrants	581,798
Exercised	(760,305)
Balance-October 31, 2019	228,178	256,411	256,411
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Balance-January 31, 2019	1,636,641	1,773,076	1,813,076
Forfeited		(136,435)
Exercised	(1,636,641)		(40,000)
Balance-October 31, 2019		1,636,641	1,773,076

Stock warrants - reconciliation

Stock warrants - reconciliation of warrant liability (Detail) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Balance at January 31, 2019	$ 5,498	$ 3,440	$ 3,440	$ 2,870
Exercised				(28)
Change in fair value of stock warrants during year	3,307	$ 1,496	2,058	$ 598
Conversion of convertible preferred stock warrants	(8,805)
Balance at October 31, 2019	$ 0		$ 5,498	$ 3,440

Fair value measurements - Addit

Fair value measurements - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jul. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0		$ 0	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0		0	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0		0	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0		0	$ 0	0
Warrant liability	0	$ 153,041	5,498		3,440	$ 2,870
Other Assets Other [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts, Assets					$ 82
Accounts Payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts	$ 24		$ 143

Fair value measurements - Sched

Fair value measurements - Schedule of weighted-average to determine the fair value of warrants (Detail) - Black Scholes Model [Member] - Fair Value Warrant Liability Member [Member] - $ / shares	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Redeemable Series A Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock	$ 18	$ 5.80	$ 4.17
Exercise price	$ 6.33	$ 2.88	$ 2.88
Remaining term (in years)	6 years 6 months 18 days	7 years 3 days	8 years 3 days
Risk-free interest rate	1.90%	2.60%	2.40%
Expected volatility	45.90%	45.10%	37.80%
Dividend yield	0.00%	0.00%	0.00%
Junior Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock	$ 18	$ 4.88	$ 2.38
Exercise price	$ 0.01	$ 0.01	$ 0.15
Remaining term (in years)	1 year 1 month 17 days	1 year 7 months 6 days	2 years 3 months
Risk-free interest rate	1.90%	2.50%	1.80%
Expected volatility	45.90%	45.10%	38.80%
Dividend yield	0.00%	0.00%	0.00%
Redeemable Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock		$ 0.01	$ 0.79
Exercise price		$ 0.01	$ 0.11
Remaining term (in years)		1 year 7 months 6 days	2 years 3 months
Risk-free interest rate		2.50%	1.80%
Expected volatility		45.10%	38.80%
Dividend yield		0.00%	0.00%

Commitments and contingencies -

Commitments and contingencies - Additional information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Commitments And Contingencies [Line Items]
Operating lease rent expense	$ 1,373	$ 1,350	$ 1,795	$ 1,640
Capital lease interest expense	$ 215	$ 190	$ 290	$ 211
Minimum [Member]
Commitments And Contingencies [Line Items]
Lease period	30 months		30 months
Maximum [Member]
Commitments And Contingencies [Line Items]
Lease period	36 months		36 months

Commitments and contingencies_2

Commitments and contingencies - Schedule of aggregate minimum net rental payments (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2020		$ 1,736
2020 (Remaining three months)	$ 443
2021	1,824	1,751
2022	819	745
2023	464	225
Total operating lease payments	$ 3,550	$ 4,457

Commitments and contingencies_3

Commitments and contingencies - Schedule of minimum lease payments (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
2020 (Remaining three months) Year ending January 31,	$ 611
2020		$ 2,282
2021	2,404	1,767
2022	1,621	984
2023	200
Total capital lease payments	4,836	5,033
Less amounts representing interest	(452)	(763)
Total capital lease payments, net of interest	4,384	4,270
Less current portion	(2,413)	(1,869)	$ (1,662)
Total capital lease payments, net of interest and current portion	$ 1,971	$ 2,401	$ 652

Income taxes - Company's Deferr

Income taxes - Company's Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Jan. 31, 2019	Jan. 31, 2018
Deferred tax assets
Net operating losses	$ 29,068	$ 27,464
Stock options	516	274
Other	276	248
Vacation	111	104
Reserve for bad debts	73	55
Disallowed interest expense	415
Depreciation	278
Total Deferred tax assets	30,737	28,145
Deferred tax liability-depreciation		(437)
Deferred contract acquisition costs	(849)	(607)
Total net deferred tax asset	29,888	27,101
Less valuation allowance	(29,888)	(27,101)
Net deferred tax asset	$ 0	$ 0

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Income Tax Disclosure [Abstract]
Accumulated a Federal net operating loss carryforward		$ 100,000	$ 93,000
Operating loss carryforwards expiration date		Dec. 31, 2029
Research and development tax credits		$ 25
Research and development tax credits expiration date		Dec. 31, 2032
Valuation Allowances, Period Increase (Decrease)		$ 2,800
Effective tax rate	0.00%	21.00%	35.00%
U.S. statutory tax rate	21.00%

Net loss per share attributable

Net loss per share attributable to common stockholders - Schedule of earnings per share basic and diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Numerator:
Net loss	$ (2,437)	$ (7,493)	$ (6,695)	$ (4,172)	$ (2,587)	$ (3,224)	$ (16,625)	$ (9,983)	$ (15,062)	$ (18,192)
Preferred stock dividend paid							(14,955)	0
Accretion of Convertible Preferred to redemption value							(56,175)	(20,962)	(30,199)	(19,981)
Net loss attributable to common stockholders							$ (87,755)	$ (30,945)	(45,261)	(38,173)
Net loss attributable to common stockholders									$ (45,261)	$ (38,173)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted							15,007,247	1,176,833	1,844,929	1,538,600
Net loss attributable to common stockholders							$ (5.85)	$ (26.30)	$ (24.53)	$ (24.81)

Net loss per share attributab_2

Net loss per share attributable to common stockholders - Schedule of antidilutive securities excluded from computation of earnings per share (Detail) - shares	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,873,284	31,243,852	31,205,249	31,477,391
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount			25,311,535	25,311,535
Stock Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount			5,055,505	5,291,791
Warrants To Purchase Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		581,798	581,798	617,654
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	228,178	256,411	256,411	256,411
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		25,311,535
Stock Options to Purchase Common Stock and Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,645,106	5,094,108

Net loss per share and unaudi_3

Net loss per share and unaudited pro forma net loss per share attributable to common stockholders - Additional Information (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2019USD ($)$ / sharesshares
Earnings Per Share [Abstract]
Conversion upon the initial public offering of all outstanding shares of Convertible Preferred | shares	25,311,535
Cashless exercise of a warrant to purchase | shares	116,232
Fair market value of the Company's common stock	$ 36,959
Warrant initial public offering price	16
Unaudited pro forma basic and diluted net loss per share	$ 1,129,539
Proceeds to pay the dividend amount | $	$ 18,073
Initial public offering price	$ 16

Net loss per share and unaudi_4

Net loss per share and unaudited pro forma net loss per share attributable - Schedule of unaudited pro forma earnings per share, basic and diluted (Detail) - USD ($)	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Numerator:
Net loss attributable to common stockholders	$ (87,755,000)	$ (30,945,000)	$ (45,261,000)	$ (38,173,000)
Accretion of preferred stock	$ 56,175,000	$ 20,962,000	30,199,000	$ 19,981,000
Change in fair value of warrant			177,000
Pro Forma net loss attributable to common stockholders, basic and diluted			(14,885,000)
Assumed conversion of preferred stock			25,311,535
Cashless exercise of warrants			$ 36,959
Share assumed issued to pay dividends			1,129,539
Pro Forma weighted-average common shares outstanding, basic and diluted			28,322,962
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	15,007,247	1,176,833	1,844,929	1,538,600
Pro Forma adjustments:
Pro Forma net loss per share attributable to common stockholders, basic and diluted			$ (0.53)

Retirement Savings Plan - Addit

Retirement Savings Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Retirement Benefits [Abstract]
Company contributions	$ 0	$ 0

Related party transactions - Ad

Related party transactions - Additional Information (Detail) - Affiliated Entity [Member] - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Related Party Transaction [Line Items]
Recognized revenue	$ 4,098	$ 3,693	$ 5,181	$ 4,882
Accounts receivable	$ 1,277		$ 598	$ 526

Acquisition - Additional Inform

Acquisition - Additional Information (Detail) - Vital Score [Member] - USD ($) $ / shares in Units, $ in Thousands	Dec. 04, 2018	Dec. 04, 2018	Jan. 31, 2019	Jan. 31, 2018
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration	$ 1,540		$ 1,540
Common stock issued	40,327		20,164
Business combination equity vested, percentage	50.00%	50.00%
Percentage of shares to be acquired	50.00%	50.00%
Business acquisition shares value, per shares	$ 8.03	$ 8.03	$ 8.03
Contingent consideration	$ 750	$ 750
Common stock and contingent consideration upon the principals, percentage	50.00%
Business acquisition revenue		100		$ 250
Business acquisition net loss		$ 600		$ 455
Acquired technology and customer relationships [Member]
Business Acquisition, Contingent Consideration [Line Items]
Weighted average amortization period			5 years 9 months 18 days
Acquired technology and customer relationships [Member] | Minimum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Amortization period			5 years
Acquired technology and customer relationships [Member] | Maximum [Member]
Business Acquisition, Contingent Consideration [Line Items]
Amortization period			7 years
Payable upon the closing of the acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration	$ 1,190
Payable on the first anniversary [Member]
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration	$ 350

Acquisition - Summary of Purcha

Acquisition - Summary of Purchase Price Consideration Based on Estimated Acquisition Fair Value (Detail) - Vital Score [Member] - USD ($) $ in Thousands	Dec. 04, 2018	Jan. 31, 2019
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration	$ 1,540	$ 1,540
Common stock issued, amount, (20,164 shares at $8.03 per share)		162
Total fair value of acquisition consideration		$ 1,702

Acquisition - Summary of Purc_2

Acquisition - Summary of Purchase Price Consideration Based on Estimated Acquisition Fair Value (Parenthetical) (Detail) - Vital Score [Member] - $ / shares	Dec. 04, 2018	Jan. 31, 2019
Business Acquisition, Contingent Consideration [Line Items]
Common stock issued, shares	40,327	20,164
Common stock issued, per shares	$ 8.03	$ 8.03

Acquisition - Schedule of final

Acquisition - Schedule of final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Acquisition Date [Line Items]
Goodwill	$ 251	$ 250	$ 0
Vital Score [Member]
Acquisition Date [Line Items]
Property and equipment		5
Acquired technology		490
Customer relationships		980
Goodwill		250
Total assets acquired		1,725
Accounts payable		(23)
Total purchase price		$ 1,702

Subsequent events - Additional

Subsequent events - Additional Information (Detail)	Mar. 25, 2019$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
RSU's granted	390,794
Expiration date	2026-03
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 1 [Member]
Subsequent Event [Line Items]
Percentage of vest option	10.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 2 [Member]
Subsequent Event [Line Items]
Percentage of vest option	20.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 3 [Member]
Subsequent Event [Line Items]
Percentage of vest option	30.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 4 [Member]
Subsequent Event [Line Items]
Percentage of vest option	40.00%
Subsequent Event [Member] | Employees And Director [Member]
Subsequent Event [Line Items]
Expiration date	2029-03
Stock Option Issued	962,596
Options Exercise Price Per Unit | $ / shares	$ 8.03
Subsequent Event [Member] | Employees And Director [Member] | Minimum [Member]
Subsequent Event [Line Items]
vesting term	4 years
Subsequent Event [Member] | Share-based Payment Arrangement, Year 5 [Member] | Employees And Director [Member]
Subsequent Event [Line Items]
Percentage of vest option	25.00%
Subsequent Event [Member] | 2018 Stock Option Plan [Member]
Subsequent Event [Line Items]
Number of shares available for issuance	3,048,490
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
RSU's granted	390,794
Expiration date	2026-03
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 1 [Member]
Subsequent Event [Line Items]
Percentage of vest option	10.00%
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 2 [Member]
Subsequent Event [Line Items]
Percentage of vest option	20.00%
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 3 [Member]
Subsequent Event [Line Items]
Percentage of vest option	30.00%
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 4 [Member]
Subsequent Event [Line Items]
Percentage of vest option	40.00%

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 91,968	$ 73,406	$ 99,889	$ 79,834
Capitalized contract cost, amortization	1,465	1,179	1,640	1,389
Selling and Marketing Expense [Member]
Revenue From Contract With Customer [Line Items]
Capitalized contract cost, amortization	1,465	1,179	1,640	1,389
Subscription And Related Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	41,292	31,391	$ 43,928	$ 32,430
Onsite Kiosks [Member] | Subscription And Related Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 4,462	$ 3,388

Revenues - Rollforward of contr

Revenues - Rollforward of contract assets and contract liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 636	$ 107	$ 78
Amount transferred to receivables from contract assets	(576)	(86)	(68)
Contract asset additions	918	615	96
Ending balance	978	636	107
Beginning balance	6,488	4,886	5,605
Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period	(11,168)	(4,298)	(3,609)
Increases due to invoicing prior to satisfaction of performance obligations	10,006	5,900	2,890
Ending balance	$ 5,326	$ 6,488	$ 4,886

Revenues - Schedule Of Deferred

Revenues - Schedule Of Deferred contract acquisition costs (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Jan. 31, 2018	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 3,194	$ 2,334	$ 2,334	$ 1,950
Additions to deferred contract acquisition costs	1,414		2,500	1,773
Amortization of deferred contract acquisition costs	(1,465)	(1,179)	(1,640)	(1,389)
Ending balance	3,143		3,194	2,334
Deferred contract acquisition costs, current (to be amortized in next 12 months)					$ 1,631	$ 1,673	$ 1,640
Deferred contract acquisition costs, non current					1,512	1,521	694
Total deferred contract acquisition costs	$ 3,143	$ 2,334	$ 3,194	$ 2,334	$ 3,143	$ 3,194	$ 2,334

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Restricted Stock Units (Detail) - Restricted Stock [Member]	9 Months Ended
	Oct. 31, 2019shares
Balance-January 31, 2019	20,164
Granted	526,382
Forfeited	(22,185)
Balance-October 31, 2019	524,361

Stock warrants - Additional inf

Stock warrants - Additional information (Detail) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended
	Sep. 30, 2019	Jul. 31, 2019	Oct. 31, 2019	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants	75,137	256,411
Common stock withheld	22,114	25,919
Securities called by warrants			428,757
Common stock warrants outstanding		$ 153,041	$ 0	$ 5,498	$ 3,440	$ 2,870
Shares issued upon exercise of warrants	53,023	230,492
Common Stock [Member]
Class of Warrant or Right [Line Items]
Conversion of preferred stock warrants to common stock warrants			581,798
Common stock warrants outstanding		$ 228,178
Warrant [Member]
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants		428,757
Common stock withheld		70,485